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CHAPTER 1 
 
  GENERAL INTRODUCTION 
 
Metabotropic glutamate receptors 
 
Glutamate is not only one of the 22 proteinogenic amino acids, but also the major 
excitatory neurotransmitter in the central nervous system (CNS). The glutamate receptors 
can be divided into two classes: the ionotropic glutamate receptors and the metabotropic 
glutamate receptors. While the ionotropic glutamate receptors (AMPA receptors, NMDA 
receptors and kainate receptors) mediate fast responses elicited by glutamate, the 
metabotropic glutamate (mGlu) receptors provide a mechanism by which glutamate can 
transduce environmental cues and modulate synaptic transmission via second messenger 
signaling pathways with slower time course. Because of their widespread distribution 
especially in the CNS, pharmacological manipulation of mGlus may represent ideal 
therapeutic interventions for a wide range of neurological and psychiatric disorders 
(Reviewed in (Gregory et al., 2013; Niswender and Conn, 2010)). 
 
Classification of mGlus 
 
The Seven Transmembrane Spanning/G Protein Coupled Receptors (7TMR/GPCR) 
account for 4% of the entire protein-coding genome (Bjarnadottir et al., 2006) and 
represent the targets of approximately 40-50% of medicinal drugs on the market 
(Thomsen et al., 2005). The core function of GPCRs is to serve as a transducer of signals 
from the extracellular environment to the intracellular machinery that aggregates to 
govern organismal responses. The GPCR superfamily can be classified into several 
classes: the Class A GPCRs (or Rhodopsin-like receptors) account for almost 85% of the 
GPCR genes, the Class B GPCRs (or secretin-like receptors) include 15 receptors and are 
regulated by peptide hormones, and the Class C GPCRs, which are characterized by a 
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large extracellular N-terminal domain and contain 22 distinct receptors. The Adhesion, 
Frizzled, Taste type-2 and other unclassified receptors comprise the rest of the 
superfamily (Bjarnadottir et al., 2006). 
      
The mGlus belong to the Family C GPCRs, which also encompasses calcium sensing 
receptors, the GABAB receptor, taste receptors and other orphan Class C receptors. Since 
the cloning of rat mGlu1 in 1991, 8 mGlu subtypes have been cloned thus far, named 
mGlu1 through mGlu8. Within the family, the eight mGlu subtypes can be further 
classified into three groups (Table 1.1), with an intragroup sequence homology of about 
70% and an intergroup sequence homology of about 45% (reviewed in (Conn and Pin, 
1997)). The group I mGlus include mGlu1 and mGlu5, group II includes mGlu2 and 
mGlu3, whereas mGlu4, 6, 7 and 8 comprise the group III mGlus. Such classification is 
further confirmed by the G-protein coupling and pharmacological profile of the three 
groups. While the group I mGluRs are coupled to Gq, the group II and group III are 
coupled to Gi/o G proteins.  
 
In addition to the G protein-coupling specificity, the three groups of mGlus also differ in 
their expression patterns. With the exception of mGlu6 which is expressed exclusively in 
ON-bipolar cells in the retina, all mGlus are widely expressed in many locations within 
the brain. Group I mGlus are primarily expressed postsynaptically to modulate neuronal 
excitability, whereas group III mGlus are typically located presynaptically. Both pre- and 
postsynaptic expression has been detected for group II mGlus. In addition, mGlu3 and 
mGlu5 are also expressed in astrocytes. Expression of each mGlu subtypes has been 
mapped using immunohistochemistry. Specifically, high mGlu1 expression was detected 
in the olfactory bulb, CA1 hippocampus, globus pallidus, thalamus and cerebellum 
(Petralia et al., 1997). Expression of mGlu5 was found in the olfactory bulb, olfactory 
tubercle, cerebral cortex, hippocampus, striatum and nucleus accumbens (Shigemoto et 
al., 1993). For mGlu2 and mGlu3, significant staining was found in the cerebral cortex, 
hippocampus, thalamus and caudate-putamen (Petralia et al., 1996). mGlu4 is highly 
enrich in the molecular layer of cerebellum, but is also expressed in globus pallidus 
substantia nigra and moderately in neocortex, hippocampus, striatum and thalamus  
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Classification G protein 
coupling 
Receptor 
Subtypes 
Splice 
Variants 
Selective Ligands 
Group I Gq/11 mGlu1 mGlu1a-h,  
mGlu1g393 
mGlu1g620  
Taste mGlu1 
LY367385 (orthosteric agonist) 
Bay 36–7620 (NAM) 
Ro 67–7476 (PAM) 
Ro 67–4853 (PAM) 
VU71 (PAM) 
mGlu5 mGlu5a,b CHPG (orthosteric agonist) 
MPEP (NAM) 
MTEP (NAM) 
CDPPB (PAM) 
CPPHA (PAM) 
VU0365396 (SAM) 
Group II Gi/o mGlu2 mGlu2 LY487379 (PAM) 
BINA (PAM) 
mGlu3 GRM3Δ2  
GRM3Δ4 
GRM3Δ2Δ3  
ML337 (NAM) 
Group III Gi/o mGlu4 mGlu4a,b 
Taste mGlu4 
LSP1-2111 (orthosteric agonist) 
LSP4-2022 (orthosteric agonist) 
PHCCC (PAM) 
VU0155041(PAM) 
VU0364770 (PAM) 
ADX88178 (PAM) 
mGlu6 mGlu6a-c  
mGlu7 mGlu7a-e AMN 082 (allosteric agonist) 
MMPIP (NAM) 
ADX71743 (NAM) 
mGlu8 mGlu8a-c (S)-3,4-DCPG (orthosteric agonist) 
AZ12216052 (PAM) 
 
Table 1.1. Classification, G protein coupling, splice variants and selective ligands for 
mGlu subtypes. 
 
	   4	  	  
(Bradley et al., 1999). mGlu7 is abundantly expressed in striatum, globus pallidus, and 
substantia nigra pars reticulata (Kosinski et al., 1999), whereas mGlu8 is expressed 
primarily in hippocampus and piriform cortex (Ferraguti et al., 2005; Kinoshita et al., 
1996). mGlu receptors also expressed in peripheral tissues and play important roles in 
pathological conditions including congenital stationary night blindness (Mathiesen et al., 
2005; Zeitz et al., 2007) and malignant transformation, such as melanoma (Choi et al., 
2011; Pollock et al., 2003). 
 
Different mGlu subtypes have been suggested to colocalize at various synapses. Previous 
immunohistochemistry and in situ hybridization studies suggest that mGlu2 and mGlu4 are 
co-localized in several brain regions (Bradley et al., 1999; Neki et al., 1996; Ohishi et al., 
1995; Ohishi et al., 1993) and mGlu2 is also functionally expressed at corticostriatal 
synapses (Johnson et al., 2005). 
 
All mGlu subtypes have been discovered to undergo alternative splicing, primarily at the 
C-terminus, and some of the better characterized splice variants are described below. In 
humans, 8 different splice variants of mGlu1 exist, named mGlu1a, 1b, 1c, 1d, 1e, 1g, 1g-393, 1g-620 
and 1h. Two newly identified exons in human GRM1 express a novel splice variant of 
metabotropic glutamate 1 receptor. mGlu1a is the longest variant and the others result 
from differential splice site usage, generating distinct isoforms with differing C-termini 
(reviewed in (Hermans and Challiss, 2001)). The splice variant containing only the VFD 
has been shown to act as a dominant negative, preventing full length mGlu1 isoforms 
from signaling (Beqollari and Kammermeier, 2010).  Also within the group I mGlus, 
mGlu5a and mGlu5b are two splice variants for mGlu5 with similar pharmacological 
profiles (Joly et al., 1995; Minakami et al., 1994). Three splice variants of mGlu3 exist in 
human brain due to exon skipping events: GRM3Δ2 (lacking exon 2), GRM3Δ4 (lacking 
exon 4), and GRM3Δ2Δ3 (lacking exons 2 and 3).  Among the three variants, GRM3Δ4 
is most abundantly expressed and represents an mGlu3 receptor without a seven-
transmembrane domain, which may have unique functions and relate to non-coding 
single nucleotide polymorphisms (SNPs) in patients with cognitive dysfunction (Sartorius 
et al., 2006). As to the group III mGlus, the mGlu4 gene was described as undergoing 
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alternative splicing to generate mGlu4a and mGlu4b (Thomsen et al., 1997); however, this 
result has not been  replicated by other groups (Corti et al., 2002). Three mGlu6 splice 
variants exists in human retina, with mGlu6b lacking 97 nucleotides from exon 6 and 
mGlu6c including 5 nucleotides from intron 5 (Valerio et al., 2001). Both mGlu7 and 
mGlu8 can undergo alternative splicing at the C-terminus, resulting in at least 5 splice 
variants for mGlu7 and 2 variants for mGlu8 (Corti et al., 1998; Schulz et al., 2002). In 
addition, another splice variant, mGlu8c, contains a 74 nucleotide insertion, resulting in a 
frame shift and termination of the polypeptide before the seven transmembrane domains 
(Malherbe et al., 1999). As the C-terminal intracellular domain plays important roles in 
protein-protein interactions and signal transduction, different splice variants may possess 
distinct profiles with regards to receptor activation, receptor modification and receptor 
internalization (Enz, 2012). With the advances in sequencing technology, the diversity of 
mGlu splice variants is increasing rapidly. For example, 7 splice variants have been 
predicted for mGlu4 according to Ensembl genome database, although their existence still 
needs to be validated experimentally. 
 
Several isoforms of mGlus also exist due to alterations at the N-terminus; for example, 
Taste mGlu1 and Taste mGlu4 (Chaudhari et al., 2000), which play roles in detecting the 
taste of umami. These receptor variants, with approximately 50% of the N-terminus 
truncated, are expressed in taste buds. Compared to full-length receptors, these N-
truncated variants lack much of the glutamate binding domain and thus exhibit lower 
potency when activated by glutamate (Chaudhari et al., 2000). 
 
The structure of mGlus 
 
General structural features of mGlus 
 
As members of the Family C 7TMRs, the mGlus are characterized by a large N-
terminal domain, commonly referred to as the Venus Flytrap Domain (VFD). 
Studies of the crystal structures of the mGlu1, 3 and 7 VFDs reveal that each VFD 
contains two lobes, which together form a clam shell-like structure, with the 
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glutamate binding site found between the two lobes (Acher and Bertrand, 2005; 
Kunishima et al., 2000; Muto et al., 2007; Tsuchiya et al., 2002). Besides glutamate, 
the VFDs of some mGlus also bind other endogenous agonists of mGlus, such as 
cinnabarinic acid (Fazio et al., 2012) and L-serine-O-phosphate (Klunk et al., 1991) 
(Hampson et al., 1999), as well as magnesium and calcium, which can modulate 
receptor activity (Francesconi and Duvoisin, 2004; Kubo et al., 1998; Kunishima et 
al., 2000). Both structural (Kunishima et al., 2000; Muto et al., 2007; Tsuchiya et al., 
2002) and biochemical data (Romano et al., 1996) suggest that the VFDs from two 
distinct mGlu receptors sit back to back and dimerize together. Upon ligand binding, 
large conformational changes lead to closure of the two lobes.  Closure of one or 
both VFDs within each mGlu dimer initiates receptor activation (Kniazeff et al., 
2004). 
 
Connecting the VFD and the seven transmembrane spanning domain (7TMD) is the 
cysteine-rich domain (CRD). Based on structural studies with mGlu2, the CRD 
contains 9 cysteine residues; 8 of them form internal disulfide bonds to stabilize the 
structure of this domain. In addition, the ninth cysteine forms a disulfide bond linked 
to the VFD (Muto et al., 2007), such that the CRD senses the conformational 
changes induced by ligand binding and transmits it to the 7TMD. The 7TMD and 
intracellular loops play important roles in receptor-G protein coupling and receptor 
modulation. It has been shown that a single mutation in the 7TMD that disrupts the 
hydrogen-bonding network in TM6 and TM7 induces high constitutive activity of 
mGlu8 (Yanagawa et al., 2013), suggesting that TM6 and TM7 constrain the receptor 
in an inactive conformation and that rearrangement between these two helixes is 
critical for receptor activation. The 7TMD also provides an opportunity to modulate 
receptor activity at a site other than the traditional agonist-binding VFD. All mGlu 
small molecule allosteric modulators discovered to date are believed to bind to 
receptor 7TMDs. Classification, action and therapeutic implications of such 
allosteric modulators will be discussed in the following sections. The intracellular 
loops of mGlus are involved in G protein coupling and receptor phosphorylation. 
Specifically, the second intracellular loop is implicated in G protein coupling 
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specificity of the mGlus (Gomeza et al., 1996; Havlickova et al., 2003; Pin et al., 
1994), which is usually the function of the third intracellular loop for Class A, 
rhodopsin-like receptors.  
 
The C-terminal domain of the mGlus is within close proximity to the inner leaflet of 
the lipid bilayer. Although recent structural studies of the purified intracellular C-
terminal domains from mGlu6, 7 and 8 suggest that the C-termini of unliganded mGlus 
are mediated by linear motifs rather than secondary/tertiary structures (Seebahn et al., 
2011), these intracellular tails of mGlus interact with various intracellular proteins, 
and are subject to alternative splicing (see section 3.1 and 3.2.2), phosphorylation, 
and SUMOylation (reviewed in (Enz, 2012)).  
 
The dimeric complex of mGlus 
 
As mentioned above, mGlus form stable, covalently linked dimers. Data suggesting 
constitutive formation of mGlu homodimers emerged as early as 1996 (Romano et 
al., 1996), and was further supported by data obtained from mGlu VFD/CRD crystal 
structures (Kunishima et al., 2000). Evidence from biochemical studies reveals that 
that one or more cysteine residues on the N-terminal extracellular domain mediate 
the covalent and non-covalent interactions between two mGlu protomers (Ray and 
Hauschild, 2000; Romano et al., 2001). In addition, several studies have shown that 
mGlus do not appear to form higher-order oligomers (Brock et al., 2007; Doumazane 
et al., 2011b), although this is the case for some other Class C 7TMRs, such as the 
GABAB receptor (Comps-Agrar et al., 2012).  
 
The activation machinery of mGlu homodimers has been studied in depth, 
particularly by Jean Philippe Pin’s group, using a quality control system adapted 
from the GABAB receptor to generate mGlu dimers bearing specific mutations 
within one of the protomers. These data suggest that closure of one VFD per dimer is 
sufficient to activate the receptor, although closure of both VFDs is required to 
achieve full activity (Kniazeff et al., 2004). When one or both VFDs are occupied, 
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the 7TM domain of either protomer can be activated through intersubunit 
rearrangement (Brock et al., 2007). These findings are consistent with the hypothesis 
that only a single 7TM domain is turned on upon activation of each homodimeric 
receptor (Goudet et al., 2005; Hlavackova et al., 2005; Hlavackova et al., 2012). 
 
Besides forming homodimers, the VFD of mGlu1 can heterodimerize with full length 
mGlu5 and vice versa (Beqollari and Kammermeier, 2010). In addition, a splice 
variant of mGlu1 that contains only the VFD functions as a dominant negative to 
potently block the signaling of full length mGlu1 or mGlu5 (Beqollari and 
Kammermeier, 2010). Unfortunately, there is a paucity of evidence demonstrating 
the extent to which heterodimers exist in vivo. The discovery of heteromers in native 
systems would dramatically shift our understanding of the functional roles of this 
important family of 7TMRs and would suggest that mGlus exhibit greater diversity 
in signaling and function than has previously been appreciated. In addition, mGlu 
receptor heteromerization could also explain discordant pharmacological findings 
observed in native brain tissue (Ayala et al., 2008; Niswender et al., 2010). 
 
Evidence for full length mGlu heterodimers initially emerged in in vitro expression 
systems (Doumazane et al., 2011a; Kammermeier, 2012). By using a time-resolved 
FRET assay, Doumazane et al. demonstrated that group I mGlus can interact with 
each other, but do not associate with group II and group III mGlu subtypes; in 
contrast, group II and III mGlu receptors can co-assemble within and outside of the 
two groups. In addition, Kammermeier’s study utilizing injected superior cervical 
ganglion cells suggests that heterodimerization may alter the pharmacology of 
mGlus and their modulators. Together, these findings indicate that the functions and 
signaling of mGlus could be much more diverse and complex than previous 
estimated, although the existence and pharmacology of mGlu heterodimers still 
needs to be established using native tissue. However, examples already exist for 
heterodimers of mGlus and Class A 7TMRs in the CNS. Gonzalez-Maeso et al. 
reported that mGlu2 receptors interact with 5-HT2A receptors through transmembrane 
helix domains and form functional complexes in brain cortex (Gonzalez-Maeso et al., 
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2008). Subsequent mutagenesis studies revealed that three residues within 
transmembrane domain 4 of mGlu2 are necessary to form the 5-HT2A-mGlu2 receptor 
heterocomplex (Moreno et al., 2012). Furthermore, hallucinogenic 5-HT2A agonists 
elicit unique responses at 5-HT2A/mGlu2 complexes, which is implicated in the 
pathogenesis of psychosis (Gonzalez-Maeso et al., 2008). However, it should be 
noted that, although the formation of mGlu2/5HT2A heterocomplexes has been 
validated by other groups, (Delille et al., 2012) the unique signal transduction 
pathways mediated by the hetereodimeric complex was not replicated. In addition, it 
was also shown that mGlu2 can interact with 5-HT2B, indicating that complex 
formation is not specific to the 5-HT2A-mGlu2 pair and challenging the biological 
relevance of the 5-HT2A-mGlu2 complex. 
 
Signaling of mGlus  
 
As shown in Figure 1.1, mGlu receptors signal to intracellular machinery through both G 
protein-dependent and independent pathways.  
 
G protein-dependent signaling 
 
Classically, group I mGlus are generally coupled to Gq/11 and activate phospholipase 
Cβ, which hydrolyses phosphotinositides into inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol, a pathway leading to calcium mobilization and activation of protein 
kinase C (PKC). Other effectors downstream of Gq include phospholipase D, ion 
channels, c-Jun N-terminal kinase (JNK), mitogen-activated protein 
kinase/extracellular receptor kinase (MAPK/ERK), and the mammalian target of 
rapamycin (mTOR) pathway (Li et al., 2007; Page et al., 2006; Sayer, 1998; Servitja 
et al., 1999) (Figure 1.1). In addition, evidence has emerged that group I mGlus can 
also activate Gs and Gi/o and their downstream pathways, and that distinct regions on 
the receptor are responsible for coupling of different G proteins (Francesconi and 
Duvoisin, 1998; McCool et al., 1998). 
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Figure 1.1.  Signaling pathways of mGlu receptors. The group I, II and III mGlu 
receptors induce signal transduction through both G protein-dependent and 
independent pathways, while the signaling profile of heterodimeric mGlu receptor 
remains unexplored. GKAP, guanylate kinase-associated protein; PSD-95, 
postsynaptic density protein 95; NMDAR, N-methyl-D-aspartate receptor; PI3K, 
phosphatidylinositol 3-kinase; PIKE-L, phosphatidylinositol 3-kinase enhancer-long; 
mTOR, mammalian target of rapamycin; ERK, extracellular signal-regulated kinase;  
ASK, apoptosis signal-regulating kinase; JNK, c-Jun N-terminal kinases; PIP2, 
Phosphatidylinositol 4,5-bisphosphate; DAG, diacyl-glycerol; IP3, inositol 1,4,5-
trisphosphate; ER, endoplasmic reticulum; PKC, protein kinase C; AC, adenylate 
cyclase; PKA, protein kinase A. 
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As stated previously, the group II and group III mGlu receptors are coupled to Gi/o 
proteins and negatively regulate the activity of adenylyl cyclase. In addition, many 
ion channels have also been reported to be regulated by Gαi and the liberated Gβγ 
subunit (Guo and Ikeda, 2005; Kammermeier, 2012; Niswender et al., 2008a). Gi/o-
mediated activation of MAPK and phosphatidyl inositol 3-kinase (PI3 kinase) 
pathways, as supported by the inhibitory effect of pertussis toxin (Iacovelli et al., 
2002), add another level of complexity to the G protein-mediated signaling of group 
II and III mGlus. 
 
G protein-independent signaling 
 
While 7TMRs transduce signals through various cellular pathways, their 
responsiveness may also be regulated by receptor desensitization. When a receptor is 
stimulated, activated G protein-coupled receptor kinase (GRK) then initiates a 
combination of events including receptor phosphorylation, arrestin binding, and 
receptor internalization (reviewed in (Krupnick and Benovic, 1998)), providing a 
feedback mechanism that prevents receptor over-stimulation. For mGlus, such 
regulation is more thoroughly studied for group I mGlus than the other two groups. 
For example, internalization of mGlu1 has been shown to depend on GRK4 and β 
arrestin-1 (Dale et al., 2001; Iacovelli et al., 2003). Desensitization of mGlu5, 
however, seems to be dependent on GRK2 activity, suggesting different mGlu 
subtypes are regulated by distinct mechanisms (Sorensen and Conn, 2003).  
 
Besides regulating receptor desensitization, recruited β-arrestins are also well-known 
as scaffolding protein for signaling molecules. Reports have shown that active Src is 
recruited to activated 7TMRs by interaction with β-arrestin, which then results in 
phosphorylation of downstream molecules and consequently activation of the 
MAPK cascade (Luttrell et al., 1999). In addition, arrestins also directly facilitate the 
subcellular localization and activation of two MAPK cascades (the 
RAF→MEK→extracellular signal-regulated kinases (RAF-MEK-ERK) cascade and 
	   13	  	  
the apoptosis signal-regulating kinase→MKK→c-Jun N-terminal kinases (ASK-
MKK-JNK cascade)) (Pierce and Lefkowitz, 2001), further expanding the dimension 
and complexity of signal transduction upon GPCR activation. This role of arrestins 
in meditating signal transduction events has been demonstrated for mGlus as well. 
For example, activation of mGlu7 significantly reduces N-methyl D-aspartate 
receptor (NMDAR)-mediated currents in prefrontal cortex pyramidal neurons in a β-
arrestin/ERK signaling pathway-dependent manner (Gu et al., 2012). 
 
In addition, mGlu receptors also demonstrate the ability to activate signaling 
cascades through protein-protein interactions. For instance, the C-terminal domains 
of mGlu1 and mGlu5 interact with Homer proteins, a group of scaffolding proteins 
for multiprotein complexes. Besides interacting with the receptor, Homer proteins 
demonstrate binding ability with inositol-1,4,5-triphosphate (IP3) receptors, 
ryanodine receptors, transient receptor channel-1 and 4 (TRPC1, TRPC4), P/Q-type 
Ca2+ channels, Shank, the phosphoinositide 3-kinase (PI3K)enhancer-long (PIKE-L) 
etc., coupling receptor activation to other signaling components within the cell 
(Bockaert et al., 2004; Fagni et al., 2004; Rong et al., 2003). mGlu5 has been found 
to interact with the NMDA receptor via Homer and other scaffolding proteins and 
potentiate receptor activity (Attucci et al., 2001; Pisani et al., 2001; Tu et al., 1999). 
In addition, it has been shown that disruption of mGlu5–Homer interactions 
selectively blocks mGlu activation of the PI3K-Akt-mTOR pathway (Ronesi and 
Huber, 2008) and contribute to phenotypes of Fmr1 knockout mice, an animal model 
for Fragile X syndrome (Ronesi et al., 2012). Interestingly, Homer proteins include 
long Homer isoforms and short isoforms (Homer1a and Ania), which act as 
endogenous dominant-negatives and disrupt protein complexes containing the long 
Homer variant. The ratio of Homer 1a/long Homer bound to mGlu5 may associate 
with cognitive aging (Menard and Quirion, 2012) and has been shown to be altered 
in Fmr1 knockout mice (Ronesi et al., 2012). In addition, genetic deletion of 
Homer1a rescues several phenotypes in Fmr1 knockout mice, suggesting the 
importance of Homer proteins in the mechanism of Fragile X syndrome and 
potential therapeutic intervention for this disease (Ronesi et al., 2012). Besides the 
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PI3K-Akt-mTOR pathway, Homer also links mGlu5 to PIKE-L, which prevents cell 
apoptosis upon mGlu5 activation (Rong et al., 2003). Interestingly, it has been shown 
that the disruption of Homer-mGlu5 interaction reduces astrocyte apoptosis (Paquet 
et al., 2013), suggesting opposite functions of Homer in regulation of cell apoptosis 
in neurons and astrocytes. Besides the CNS, a point mutation of mGlu1 within the 
Homer binding region that has been discovered in the somatic cells of lung cancer 
patients (Esseltine et al., 2013), indicating important roles of Homer in the periphery.  
 
Another well-studied protein-protein interaction is the mGlu7-protein interacting 
with C kinase 1 (PICK1) interaction. PICK1 was discovered as a peripheral 
membrane protein that interacts with protein kinase Cα (PKCα) (Staudinger et al., 
1995). Besides PICK1, the C-terminus of mGlu7 also interacts with Ca2+-calmodulin, 
G protein βγ subunits to modulate the activity of voltage-gated Ca2+ channel and 
negatively regulate neurotransmitter release (Dev et al., 2001). Interestingly, 
phosphorylation of the receptor by PKC increases receptor binding to PICK1, which 
is required for stable surface expression of mGlu7 (Suh et al., 2013; Suh et al., 2008), 
but, at the same time, inhibits the binding of Gβγ subunits and Ca2+-calmodulin, 
providing a delicate regulatory machinery. Disruption of the mGlu7-PICK1 
interaction has been performed by genetic knock-in of an mGlu7 mutant that does 
not bind PICK1. The resulting animals exhibited significant defects in hippocampus-
dependent spatial working memory and high susceptibility to convulsant drugs 
(Zhang et al., 2008). Additionally, injection of a competing peptide to rodents also 
resulted in behavioral symptoms and EEG discharges that are characteristic of 
absence epilepsy (Bertaso et al., 2008). These data indicate that the mGlu7-PICK1 
interaction is important for regulating mGlu7 signaling and may underlie certain 
disease mechanisms, including cognitive disorders and epilepsy. 
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Allosteric modulation of mGlu 
 
Therapeutic indications of mGlu4 
 
Pharmaceutical manipulation of mGlus represent ideal therapeutic interventions for a 
wide range of neurological and psychiatric, as well as peripheral disorders, but this 
section will primarily focus on the therapeutic indication of mGlu4 for Parkinson’s 
disease (PD). PD is a debilitating neurodegenerative disorder characterized by movement 
symptoms including tremor, rigidity, bradykinesia and postural instability, as well as 
disturbances in sleep, depression and cognition (Jankovic, 2008; Johnson et al., 2009). 
The pathology of PD stems from severe degeneration of dopaminergic neurons in the 
substantia nigra pars compacta (SNc), a brain structure that plays important roles in the 
basal ganglia to control motor function (Surmeier and Sulzer, 2013). Within the basal 
ganglia, dopamine released from SNc neurons delicately controls the balance of output 
between the “direct pathway” and the “indirect pathway”, which oppose each other in 
controlling motor output in the basal ganglia. In PD patients, however, the loss of 
dopaminergic neurons leads to an overall increase of activity in the indirect pathway, 
which ultimately inhibits motor function in PD patients (reviewed in (Johnson et al., 
2009)). Thus, according to this model, a rebalancing of the basal ganglia circuitry is 
predicted to alleviate disease symptoms.  
 
The current gold standard treatment for PD is dopamine replacement therapy using L-
DOPA, the precursor of dopamine. However, long-term treatment with L-DOPA results 
in “wearing-off” of efficacy and development of side effects, such as dyskinesias and  
psychiatric complications (Chen and Swope, 2007). In addition, no treatment is available 
to delay the progression of the disease. The mGlu4 receptor is highly expressed 
presynaptically at the first synapse in the indirect pathway (the GABAergic striatopallidal 
synapse) (Bradley et al., 1999) and receives glutamate input from subthalamic nucleus, 
providing an exciting alternative approach to rebalance the basal ganglia circuitry for PD 
treatment. Administration of the group III mGlu agonists L-AP4 or L-SOP, and recently 
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the more mGlu4-selective agonists LSP1-2111 and LSP4-2022, has been shown to reduce 
GABAergic transmission at the striatopallidal synapse and demonstrate efficacy in 
several rodent PD models, including haloperidol-induced catalepsy and 6-OHDA-
induced motor deficits (Beurrier et al., 2009; Goudet et al., 2012; Macinnes and Duty, 
2008; MacInnes et al., 2004; Matsui and Kita, 2003; Valenti et al., 2003; Wittmann et al., 
2001). Recently, numerous highly selective mGlu4 PAMs have been developed from 
different chemical series and exhibit robust efficacy in preclinical rodent models. 
Administration of either PHCCC or VU0155041, two mGlu4 PAMs that bind to distinct 
binding sites on the receptor, reversed parkinsonian behavior in PD animal models, such 
as reserpine-induced akinesia as well as haloperidol-induced catalepsy (Marino et al., 
2003; Niswender et al., 2008b). In another example, VU0364770, a systemically active 
mGlu4 PAM, produced a reversal of forelimb asymmetry induced by unilateral 6-
hydroxydopamine (6-OHDA) lesion of the median forebrain bundle either alone or in 
combination with L-DOPA (Jones et al., 2012). In contrast, Lu AF21934 alone exhibited 
no effect in the akinesia induced by unilateral 6-OHDA lesion of the SNc unless a sub-
threshold dose of L-DOPA was co-administered. Similarly, ADX88178 alone had no 
impact on forelimb akinesia induced by a bilateral 6-OHDA lesion. However, 
coadministration of ADX88178 with a low dose of L-DOPA enabled a robust reversal of 
the forelimb akinesia deficit. The difference between PAMs in 6-OHDA lesion models 
could result from distinctions in the lesion protocols used by the different research groups. 
It is also possible that the discrepancy is mediated by different pharmacological profiles 
of mGlu4 PAMs. Detailed studies of PAMs using the same lesion procedure will be 
required to elucidate the mechanism for these differences.  
 
Besides a symptom-alleviating effect, mGlu4 PAMs also possess other potential benefits, 
such as potential disease-modifying efficacy and a lack of L-DOPA-mediated side effects, 
such as dyskinesia. PHCCC and VU0155041 has been shown to reduce dopaminergic 
cell death (Battaglia et al., 2006; Betts et al., 2012), possibly due to reduced excessive 
excitatory drive onto dopamine neurons, and provide the potential to slow disease 
progression. In addition, LuAF21934, a selective mGlu4 PAM related to the VU0155041 
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series, has been shown to decrease the incidence of L-DOPA-induced dyskinesia 
(Bennouar et al., 2013), further making mGlu4 an attractive target for PD treatment. 
 
 
Mechanism of allosteric modulation 
 
Through years of research, orthosteric ligands useful in determining the physiological 
roles of mGlus have been developed which display group-selectivity. However, as all 
orthosteric ligands bind to the N-terminal VFD of mGlus, which is evolutionarily 
designed to bind glutamate, it is difficult to achieve subtype selectivity since the 
glutamate binding site is highly conserved across all eight subtypes. In addition, brain 
penetration and pharmacokinetics of these orthosteric ligands can be limited by their 
amino acid-like properties. Many of these hurdles have been overcome by targeting 
allosteric binding sites on the receptors. As indicated by the name, allosteric modulators 
bind to a site other than the endogenous agonist binding site, and provide modulatory 
effects on the affinity/efficacy of the orthosteric agonist, termed cooperativity. Indeed, 
the complex structure of mGlus offers a number of possibilities to develop novel 
allosteric modulators. Because of the greater sequence divergence demonstrated at 
allosteric sites, a series of subtype-selective allosteric agonists and positive, negative or 
silent allosteric modulators (PAM, NAM or SAMs) of mGlus have been identified 
through high through-put screening campaigns ((Kinney et al., 2005; Mitsukawa et al., 
2005; Niswender et al., 2008b; Varney et al., 1999) and many others), which have greatly 
advanced studies on mGlu functions and accelerated the development of mGlu reagents 
as disease therapeutics.  
 
The mechanism of action of allosteric modulators is exemplified by the dataset shown in 
Figure 1.2, PAMs potentiate the response to orthosteric agonists by shifting the 
concentration-response curve of an orthosteric agonist to the left (with or without 
increasing the maxium response), indicating that the agonist response is being 
pharmacologically amplified. NAMs are molecules that antagonize the activity of 
agonists in a noncompetitive fashion through negative cooperativity. SAMs are neutral 
allosteric modulators that exhibit no apparent effect on agonist reponses on their own;  
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Figure 1.2. Mechanism of action of allosteric modulators. Instead of binding to the 
glutamate binding site on the N-terminal VFD, mGlu PAMs and NAMs bind to the 
7TMD on the receptor and induce selective modulating effects, which can be blocked by 
SAMs. PAMs potentiate the response to orthosteric agonists by shifting the dose response 
curve of an orthosteric agonist to the left, whereas NAMs progressively antagonize the 
activity of agonists through negative cooperativity in a noncompetitive fashion. 
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however, such compounds can block the binding and subsequent receptor modulation 
induced by PAMs or NAMs.  
 
Besides improved selectivity, PAMs and NAMs also provide some other advantages 
when compared to their orthosteric counterparts. First, the biological effects of PAMs and  
NAMs are dependent on the presence of the endogenous agonist; thus, they have the 
potential to preserve the spatial and temporal aspects of endogenous signaling. As PAMs 
which lack allosteric agonist activity will not constantly activate the receptor, they may 
also reduce the liability of receptor desensitization compared to the direct activation by 
orthosteric, or even allosteric, agonists. Allosteric modulators also bring a further 
advantage in that their modulating effect is saturable, thus providing a larger therapeutic 
window and potentially decreasing the risk of overdose. In addition, these allosteric 
molecules often possess drug-like properties and better pharmacokinetics and brain 
penetration compared to orthosteric ligands, an important feature considering the 
therapeutic indication of mGlus in CNS disorders.  
 
Thusfar, the majority of identified mGlu allosteric modulators bind to the 7TMD region 
of the receptor. Results from mutagenesis studies indicate that the mGlu allosteric 
binding site likely corresponds to the orthosteric binding site in Class A 7TMRs (Chen et 
al., 2008; Gregory et al., 2013; Litschig et al., 1999; Malherbe et al., 2003; Pagano et al., 
2000; Schaffhauser et al., 2003). Interestingly, PAMs can directly activate an N-terminal 
truncated mGlu (El Moustaine et al., 2012; Goudet et al., 2004), suggesting that VFD-
CRD region prevents PAMs from activating the receptor until glutamate is bound. The 
modulating effects induced by allosteric modulators can be quantified using operational 
models of allosterism (Gregory et al., 2012; Leach et al., 2007): 
 𝑦= 𝑏𝑎𝑠𝑎𝑙 + (𝐸! − 𝑏𝑎𝑠𝑎𝑙)(𝜏! 𝐴 𝐾! + 𝛼𝛽 𝐵 + 𝜏! 𝐵 𝐾!)!𝜏![𝐴](𝐾! + 𝛼𝛽 𝐵 + 𝜏! 𝐵 𝐾!)! + ( 𝐴 𝐾! + 𝐾!𝐾! + 𝐾! 𝐵 + 𝛼 𝐴 𝐵 )! 
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where A and B are the molar concentration of the orthosteric agonist and the allosteric 
modulator, respectively; KA and KB are the equilibrium dissociation constant of the 
orthosteric agonist and the allosteric modulator, respectively; τA and τB quantify the 
efficacy of the orthosteric agonist and the allosteric modulator, respectively. Basal, Em 
and n represent the basal system response, maximal possible system response and the 
transducer function that links occupancy to response. Importantly, these models have 
introduced two parameters, α and β, to describe cooperativity of an allosteric ligand on 
the affinity and efficacy of orthosteric agonist. The operational models of allosterism not 
only allow quantitative estimation of modulator affinity and cooperativity values, which 
can be used to guide compound optimization processes, but can be used to derive reliable 
estimates of modulator affinities when radioligand is not available (Gregory et al., 2012).  
 
Based on molecular pharmacology data, it has been hypothesized that binding of one 
PAM per mGlu dimer is sufficient to potentiate receptor activity (Goudet et al., 2005). In 
contrast, binding of NAMs to both protomers appears to be necessary to inhibit receptor 
activation (Hlavackova et al., 2005).  
 
Allosteric modulators for mGlu2 and mGlu4 
 
As allosteric modulators have been discovered for each individual mGlu subtype, 
selective modulators for mGlu2 and mGlu4 will be discussed here in detail.  
 
BINA, LY487379 (along with CBiPES) and THIIC represent three chemical scaffolds of  
highly selective mGlu2 PAMs that lacks activity at mGlu3 (Fell et al., 2011; Galici et al., 
2006; Johnson et al., 2005). Several NAMs from the dihydrobenzo[1,4]diazepin-2-one 
series, as exemplified by MNI-137, have been reported to antagonized both mGlu2 and 
mGlu3 in a non-competitive fashion (Hemstapat et al., 2007; Woltering et al., 2008a; 
Woltering et al., 2008b). Additionally, a group of mGlu2 SAMs have been identified 
through FRET-based binding assays and slight modification of these SAMs yields three 
mGlu2 NAMs with mGlu3 PAM activity, indicating that identification of SAMs is a 
useful approach to discover novel mGlu allosteric modulators (Schann et al., 2010). 
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Mutagenesis studies have revealed that amino acids that are essential for mGlu2 PAM 
activity are dispensible for NAMs, and the converse has also been reported (Lundstrom et 
al., 2011; Rowe et al., 2008; Schaffhauser et al., 2003). These data suggest that mGlu2 
PAMs and NAMs may bind to different allosteric pockets, although binding studies using 
appropriate allosteric radioligands are required to validate this hypothesis.  
 
Allosteric modulation has also been demonstrated to be a successful approach to 
selectively modulate mGlu4, 7 and 8. An mGlu1 partial antagonist, PHCCC, was the first 
identified PAM for mGlu4 with no activity on 6 of the other mGlu subtypes except for 
mGlu6 (Beqollari and Kammermeier, 2008; Maj et al., 2003; Marino et al., 2003). In the 
in vitro mGlu4 assays in which is has been examined, PHCCC exhibits no agonist activity 
by itself but increases the potency of glutamate at mGlu4 and acts as a proof-of-concept 
compound for targeting mGlu4 as a potential therapeutic strategy for disorders such as 
Parkinson’s disease (Marino et al., 2003). Further optimization of the PHCCC scaffold 
has been challenging (Niswender et al., 2008, Williams et al 2010); however, a high-
throughput screening campaign led to the identification of VU0155041 and VU0080421 
as examples of non-PHCCC scaffold mGlu4 PAMs (Niswender et al., 2008b; Niswender 
et al., 2008c). Recently, many other mGlu4 PAMs, including 4PAM-2, VU0364770, 
ADX88178, LuAF21934 and others (Bennouar et al., 2013; Drolet et al., 2011b; Jones et 
al., 2012; Le Poul et al., 2012), have emerged with significant improvements in potency, 
selectivity and pharmacokinetic profile compared to PHCCC. Particularly, VU0364770, 
ADX88178 and LuAF21934 exhibit high potency with good pharmacokinetic profiles for 
use as tool compounds; each of these ligands shows in vivo efficacy in animal models of 
PD and other disorders. Interestingly, VU0155041 also exhibits allosteric agonist activity 
at mGlu4 when tested in vitro (Niswender et al., 2008b), suggesting an alternative 
mechanism of action compared to PHCCC. Indeed, data obtained from radioligand 
binding assays has demonstrated that VU0155041 binds to a unique allosteric site on 
mGlu4 which is different from the binding site of PHCCC and 4PAM-2 (Drolet et al., 
2011b).   
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Advantages and complications of allosteric modulation 
 
In addition to the improved selectivity, PAMs and NAMs also provide some other 
advantages comparing to orthosteric counterparts. First, the biological effects of PAMs 
and NAMs are dependent on the presence of the endogenous agonist, thus they have the 
potential to preserve the spatial and temporal aspects of endogenous signaling. As PAMs 
themselves will not continuously activate the receptor, they may also reduce the liability 
of receptor desensitization comparing to the direct activation by orthosteric, or even 
allosteric, agonists. Allosteric modulators also bring a further advantage in that their 
modulating effect is saturable, thus providing a larger therapeutic window and potentially 
decreasing the risk of overdose. In addition, these allosteric molecules often possess 
drug-like properties and better permeability at the blood-brain barrier, an important 
feature considering the therapeutic indication of mGlus in CNS disorders.  
 
Despite all the advantages mentioned above, many allosteric modulators are lipophilic, 
which diminishes their solubility, can affect their pharmacokinetic profile, and potentially 
increases off-target binding. The shallow structure-activity relationship among classes of 
allosteric ligands also represents a significant hurdle in the development of allosteric 
modulators. Additionally, because of the substantial activity alteration generated by 
minor structural changes, a number of mGlu allosteric modulator classes are susceptible 
to  subtle “molecular switches” (Wood et al., 2011), by which compounds within a series 
can switch from NAM to PAM, PAM to NAM, or exhibit altered selectivity (Lamb et al., 
2011; Sharma et al., 2009; Sheffler et al., 2012; Zhou et al., 2010).  
 
Allosteric compounds have also complicated our understanding of receptor 
pharmacology. As allosteric modulators potentiate/inhibit the receptor through 
cooperativity with the orthosteric ligand being used, it is not surprising that “probe 
dependence” has been reported in some cases, in that modulators have differential effects 
depending upon the orthosteric ligand that is present (Suratman et al., 2011; Valant et al., 
2012). Although examples still have yet to be discovered for mGlu receptors, caution 
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should be taken to choose the orthosteric ligand for in vitro studies. In addition, similar to 
what has been described with some orthosteric ligands (Urban et al., 2007), many 
allosteric ligands have been found to differentially stimulate multiple signaling cascades 
downstream of a receptor (Kenakin, 2005), a phenomenon often termed “functional 
selectivity” “biased signaling”, or “ligand directed trafficking” (Marlo et al., 2009; Zhang 
et al., 2005). Indeed, 7TMRs may adopt multiple structural conformations, and allosteric 
modulators may stabilize any of them, which can translate into the regulation of some 
signaling pathways but not others.  
 
The first aim of this dissertation is to study the signaling bias of mGlu4 PAMs induced by 
concommitant activation of a Gq-coupled receptor. The second part of this dissertation is 
to study the heterodimerization of mGlu2/4 and the differentially regulated pharmacology 
of allosteric modulators by the formation of mGlu heterodimers. Although these findings 
highly complicate the application of allosteric modulators as disease therapeutics, it is 
conceivable that it could be utilized to enhance the therapeutic outcome or avoid adverse 
effects. 
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CHAPTER II 
 
FUNCTIONAL SELECTIVITY INDUCED BY MGLU4 RECEPTOR 
ALLOSTERIC MODULATORS DURING CONCOMITANT ACTIVATION OF 
Gq COUPLED RECEPTORS 
 
Introduction 
 
Seven Transmembrane Spanning/G-Protein-Coupled Receptors (7TMRs/GPCRs) 
represent the majority of drug targets currently used in clinical practice. Much interest 
has recently been placed on the discovery and characterization of allosteric modulators 
for these receptors due to several potential advantages over traditional orthosteric ligands 
in terms of drug development (reviewed in (Keov et al., 2011)). For example, many 
natural endogenous ligands are peptides or small amino acids which possess limitations 
in pharmacokinetic properties, preventing their development as drug candidates. 
Additionally, the orthosteric agonist binding sites of many 7TMRs are highly conserved 
across family members, making selectivity for a particular receptor within one group 
difficult to achieve. Due to their interaction with the receptor at a site distinct from the 
orthosteric site, allosteric ligands often possess very high receptor selectivity. Allosteric 
modulators also have the ability to provide a more subtle and physiologically-relevant 
approach to increasing or decreasing target activity because receptor regulation will occur 
only in the presence of the endogenous ligand (Bridges and Lindsley, 2008; Conn et al., 
2009). Furthermore, allosteric potentiators, or positive allosteric modulators (PAMs), 
may, in some cases, avoid receptor desensitization and/or down-regulation that can occur 
after chronic administration of an orthosteric agonist (Bridges and Lindsley, 2008; Conn 
et al., 2009). As allosteric modulators function by exerting either positive (PAMs) or 
negative (NAMs) cooperativity with the orthosteric ligand, mechanistically they will 
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exhibit a “ceiling” effect (i.e., maximal receptor occupancy may not translate to maximal 
effect on receptor activation), which may avoid target/mechanism-mediated side effects 
that could arise from accidental overdose. 
 
While allosteric modulators of 7TMRs provide potential advantages/distinctions over 
orthosteric ligands, these compounds also greatly complicate our understanding of 
receptor pharmacology.  In recent years, there has been a growing appreciation of the 
ability of a single 7TMR to simultaneously regulate multiple signaling cascades (Kenakin, 
2005), some of which are G protein-independent, such as β arrestin-regulated pathways. 
This phenomenon, now well established for orthosteric ligands, has been termed 
“functional selectivity”, “biased signaling”, or “ligand directed trafficking” (Keov et al., 
2011; Urban et al., 2007); we will refer to this phenomenon as functional selectivity. 
There are now also clear examples of 7TMR allosteric modulator-mediated functional 
selectivity (Marlo et al., 2009; Mathiesen et al., 2005). While this behavior introduces 
complexity into ligand development, it is anticipated that capitalizing on functionally 
selective effects will provide exciting opportunities to tailor new drug therapy to 
specifically regulate coupling of 7TMRs to beneficial signaling pathways but not others, 
potentially reducing adverse effects. 
 
There are numerous mechanisms by which functionally selective pharmacology can be 
induced by allosteric ligands. For example, 7TMRs have the ability to adopt multiple 
structural conformations, any of which might be stabilized by an allosteric modulator. 
This can translate into the ability of a modulator to preferentially regulate some pathways 
and not others based on the particular conformation they stabilize. Receptor activity is 
also regulated by other cellular proteins, such as G-proteins, arrestins, or scaffolding 
proteins, which also act in an allosteric fashion to affect receptor conformations. In this 
case, compound pharmacology can be altered depending on the context in which a 
receptor is expressed (e.g., (Niswender et al., 2010)), presumably due to the different 
proteins or cellular components interacting with the receptor in various cell types.  
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An alternate possibility that may affect the outcome of functional selectivity would be 
convergent signaling pathways that are activated (or inhibited, or simply absent) in a 
certain temporal or spatial context. It has previously been demonstrated that activation of 
the Gi/o-coupled GABAB receptor, in conjunction with the Gq- coupled metabotropic 
glutamate 1 (mGlu1) receptor, produces a signaling convergence at the level of 
phospholipase C β3 (PLCβ3) to induce potentiated calcium mobilization (Pin et al., 2009; 
Rives et al., 2009). In these studies, this phenomenon was not due to  
heterodimerization/oligomerization of the receptors, was generalizable to other receptor 
pairs, and was demonstrated to exhibit functional relevance in cerebellar Purkinje cells 
and cultured cortical neurons where these two receptors are co-expressed (Rives et al., 
2009). In the current study, we extend these findings to explore potentially functionally 
selective effects induced by this type of signaling convergence. We describe that, as for 
the GABAB and mGlu1 receptor combination, activation of a Gq coupled histamine 
receptor, the H1 receptor, dramatically potentiates the ability of the Gi/o-coupled 
metabotropic glutamate 4 (mGlu4) receptor to induce intracellular calcium mobilization. 
However, histamine does not potentiate the ability of mGlu4 activation to modulate other 
“common” Gi/o-regulated signaling cascades, such as cAMP inhibition. These results 
suggest that H1 co-activation biases mGlu4-mediated signaling events toward certain 
signaling pathways. Furthermore, when small molecule PAMs of mGlu4, are included in 
these assays, the potentiated signaling of mGlu4 is further biased by histamine toward 
calcium-dependent pathways. Our results suggest that convergence of these signaling 
pathways may result in substantial, and potentially unexpected, increases in calcium 
responses downstream of mGlu4 activation, particularly when receptor activity is 
potentiated using positive allosteric modulators. 
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Methods 
 
Cell line establishment and cell culture  
 
Establishment and culture of the human mGlu4 (hmGlu4)/Gqi5/CHO-DHFR(-) has been 
described in (Niswender et al., 2008b). All cell culture reagents were purchased from 
Invitrogen (Carlsbad, CA) unless otherwise noted.  
 
Guinea pig H1 (gp H1)/CHO-K1 cells were obtained by stable transfection of CHO-K1 
cells with guinea pig H1 receptor in pcDNA3.1 vector (a generous gift of Mike Zhu, Ohio 
State University). Single G418-resistant clones were isolated and screened for H1-
mediated calcium mobilization as described below. Monoclonal gpH1/CHO-K1 cells 
were cultured in 90% Dulbecco's modified Eagle's medium (DMEM), 10% dialyzed fetal 
bovine serum (FBS), 100 U/ml penicillin/streptomycin, 20 mM HEPES, 1 mM sodium 
pyruvate, 2 mM L-glutamine, 20 µg/ml proline (Sigma-Aldrich, Inc., St. Louis, MO) and 
400 µg/ml G418 sulfate (Mediatech, Inc., Herndon, VA).  
 
Rat mGlu4/CHO-K1 cells, rat mGlu2/CHO-K1 cells, rat mGlu4/H1/CHO-K1 cells, and rat 
mGlu2/H1/CHO-K1 cells were obtained by stable transfection of either CHO-K1 cells or 
gpH1/CHO-K1 cells with rat mGlu4 or mGlu2 receptor in a pIRESpuro3 vector 
(Invitrogen). Polyclonal cells were cultured in 90% DMEM, 10% dialyzed FBS, 100 
U/ml penicillin/streptomycin, 20 mM HEPES, 1 mM sodium pyruvate, 2 mM L-
glutamine, 20 µg/ml proline (Sigma-Aldrich, Inc., St. Louis, MO), 20 µg/ml puromycin 
(Sigma-Aldrich, Inc., St. Louis, MO) without or with 400 µg/ml G418 sulfate (for H1 
expressing cell lines, Mediatech, Inc., Herndon, VA). 
 
Rat mGlu4/M1/CHO-K1 cells were generated by stable transfection of rat mGlu4/CHO-
K1 cells with rat M1 muscarinic receptor DNA in pcDNA3.1 vector. Polyclonal cells 
were cultured in 90% DMEM, 10% dialyzed FBS, 100 U/ml penicillin/streptomycin, 20 
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mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine, 20 µg/ml proline (Sigma-
Aldrich, Inc., St. Louis, MO), 400 µg/ml G418 sulfate (Mediatech, Inc., Herndon, VA) 
and 20 µg/ml puromycin (Sigma-Aldrich, Inc., St. Louis, MO). 
 
 Calcium mobilization assays 
 
For assays performed using the Flexstation (Molecular Devices, Sunnyvale, CA), cells 
were seeded at a density of 60,000 cells/100 µl/well in Costar 96-well tissue culture-
treated plates. For assays performed using the Hamamatsu FDSS 6000 or 7000 
(Hamamatsu, Japan), cells were seeded at 30,000 cells/20 µl/well in Greiner 384-well 
clear-bottomed, tissue culture–treated plates. Cells were incubated in assay medium (90% 
DMEM, 10% dialyzed FBS, 20 mM HEPES and 1 mM sodium pyruvate) overnight at 
37°C/5% CO2 and assayed the following day.  
 
Fluo-4/acetoxymethyl ester (Invitrogen) was dissolved as a 2.3 mM stock in DMSO and 
mixed in a 1:1 ratio with 10% (w/v) Pluronic acid F-127 and diluted in assay buffer 
(Hanks' balanced salt solution, 20 mM HEPES, and 2.5 mM probenecid; Sigma-Aldrich) 
to a final concentration of 2 µM. Cells were dye-loaded for 45 min at 37°C; dye was then 
removed and replaced by appropriate volume of assay buffer. For single-add experiments, 
a series of different concentrations of glutamate or histamine were diluted into assay 
buffer as 2× stock. For histamine fold-shift and potency experiments, histamine was 
diluted as 2× stock and added at the first add. After 150 sec, the appropriate volume of a 
5× glutamate stock was added in a second addition. For experiments using antagonists or 
PAMs, compounds were added at a 2× final concentration in the first addition followed 
by the desired concentration of agonist in the second addition. 
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Total RNA isolation, reverse transcription and polymerase chain reaction (RT–
PCR)  
 
CHO-K1 cells, mGlu4/CHO-DHFR(-) cells, mGlu4/Gqi5/CHO-DHFR(-) cells, and 
mGlu4/HEK/GIRK cells were seeded in 10 cm cell culture dishes one day before the 
experiment. On the second day, cells were harvested and total mRNA from each cell line 
was extracted using an RNeasy Mini Kit (Qiagen, Valencia, CA). Total RNA was 
quantified by Nanodrop and 0.5 ug was reversely transcribed into cDNA by iScript 
cDNA Synthesis Kit (Bio-Rad, Philadelphia PA) according to the manufacturer’s 
protocol. Reactions were carried out both in the presence and in the absence of reverse 
transcriptase (as negative controls). One tenth of each yielded cDNA sample was used to 
perform polymerase chain reaction (PCR) using primers for histamine H2, H3 and H4 
receptors. The primers were designed to match the conserved sequence for human, rat 
and mouse histamine receptors:  
H2 Forward: AGCTTTGGCCAGGTCTTCTGCA 
H2 Reverse: GGCTGCCAGTGTCACGGTGG 
H3 Forward: GCTGTGGCTGGTGGTAGACT  
H3 Reverse: AGGAGCTTGGTGAAGGCTCTGCGG 
H4 Forward: TGATAGGCAATGCTGTGGTC 
H4 Reverse: GCCAGTGACCTGGCTAGCTTCCT 
 
Water was used as a negative control for PCR reactions for H2-H4 receptors. 1 ng of rat 
brain cDNA was used as the positive control for H2 and H3 receptor and pcDNA3.1-H4 
plasmid was used as positive controls for H4 receptor. The amplification protocol for H2 
and H3 was 95 °C for 2 min, 30 cycles of 95 °C for 30 s, 58 °C for 30 s, and 72 °C for 1.5 
min. For H4, the annealing temperature was set at 52°C. The final extension step was at 
72 °C for 5 min. The PCR products were then electrophoresed on a 1% agarose gel 
containing ethidium bromide in parallel with 1 Kb Plus DNA Ladder (Invitrogen). 
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Phosphoinositide hydrolysis assays 
 
mGlu2/H1/CHO-K1 cells were plated in 24-well plates at a density of 100,000 
cells/well/0.5 mL in growth medium two days before the assay. On the following day, 
growth media was removed and replace with 0.5 ml/well assay media containing 0.5 
µCi/ml [3H]-inositol. Cell plates were incubated at 37°C/5% CO2 overnight and assayed 
on the third day. For stimulation of phosphoinositide hydrolysis, the [3H]-inositol-
containing assay medium was first aspirated from wells and replaced with 200 µl of assay 
buffer (HBSS supplemented with 20 mM HEPES and 30 mM LiCl). Cells were then 
treated with 250 µl of assay buffer or histamine (2×, 1 µM final concentration, diluted in 
assay buffer) and 50 µl of serial dilutions of glutamate (10×, diluted in assay buffer). 
After drug addition, the assay plates were incubated at 37°C/5% CO2 for 1 h, and then 1 
ml of stop solution (10 mM formic acid) was added into each well to terminate the 
reaction. Cells were incubated in stop solution for 1 h at room temperature then the cell 
extracts were transferred to anion exchange columns (AG 1-X8 Resin, 100-200 mesh, 
formate form; Bio-Rad Laboratories, Hercules, CA) for separation of [3H]inositol-
containing compounds. After loading of cell extracts, each column was washed 
sequentially with 9 ml of water, 9 ml of 5 mM inositol, and 9 ml of water. Finally, the 
[3H]inositol-containing compounds that bound to columns were eluted with 9 ml of PI 
Eluent (200mM ammonium formate and 100 mM formic acid) into scintillation vials and 
measured by liquid scintillation counting. Baseline response was removed from both 
histamine-treated and control group respectively and data were fit with GraphPad Prism 
(La Jolla, CA) to a 4-parameter logistic equation.  
 
Adenylate cyclase assays 
 
Adenylate cyclase assays were performed according to the methods described in (Sheffler 
and Conn, 2008; Watts and Neve, 1996). Cells were plated at 60,000 cells/well in Assay 
Media in 96 well plates 24 h prior to assay. The next day, media was removed from the 
cells and replaced with 100 µL of serum free DMEM containing 20 mM HEPES. After 1 
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h incubation at 37 °C, the media was replaced with 50 µL 37 °C stimulation buffer 
(DMEM, 15 mM HEPES, pH 7.4, 0.025% ascorbic acid). After a 10 min incubation at 
room temperature, the stimulation buffer was removed and the cells were placed on ice. 
For dose response curves of glutamate in rat mGlu4/CHO-K1 cells and rat 
mGlu4/H1/CHO-K1 cells, 20 µL of the phosphodiesterase inhibitor 3-isobutyl-1-
methylxanthine (IBMX) (4×, 500 µM final concentration, diluted in stimulation buffer) 
was first added to all wells to prevent cAMP breakdown. 20 µL of stimulation buffer was 
then added, followed by 20 µL of forskolin (4×, 10 µM final concentration, diluted in 
stimulation buffer) or DMSO-matched vehicle control. Finally, serial dilutions of 
glutamate (20 µL, 4×, diluted in stimulation buffer) were added to the wells. For 
histamine fold-shift experiments in mGlu4/Gqi5/CHO-DHFR(-) cell line, cells were 
treated with 20 µL IBMX (4×, 500 µM final concentration, diluted in stimulation Buffer), 
20 µL stimulation buffer or histamine (4×, 10 µM final concentration, diluted in 
stimulation buffer), 20 µL of forskolin (4×, 20 µM final concentration) or vehicle and 20 
µL of serial dilutions of glutamate. For histamine fold-shift experiments in 
mGlu4/H1/CHO-K1 cells, serial dilutions of mGlu4 PAMs were diluted as 4× stock in 
stimulation buffer containing 4 µM glutamate (1 µM final concentration). Cells were 
treated with 20 µL IBMX (4×, 500 µM final concentration, diluted in timulation Buffer), 
20 µL of forskolin (4×, 20 µM final concentration) or vehicle, 20 µL stimulation buffer or 
histamine (4×, 300 nM final concentration, diluted in stimulation buffer) and 20 µL of 
serial dilutions of mGlu4 PAMs. 
 
After 20 min incubation in water bath at 37 °C, drugs were then removed from the wells 
and the reaction was terminated by addition of 40 µL ice-cold 3% trichloroacetic acid 
(TCA). Cell lysates were chilled at 4 °C for at least 2 h. Accumulated cAMP was 
quantified using a competitive binding assay adapted from (Nordstedt and Fredholm, 
1990) with minor modifications. Briefly, TCA extracts (15 µL) from assay plates were 
added to a deep well 96 well plate (Axygen Scientific) in triplicates. [3H]-cAMP 
(PerkinElmer) (1 nM final concentration) was diluted in cAMP Assay Buffer (100 mM 
Tris–HCl, pH 7.4, 100 mM NaCl, 5 mM EDTA) and added to each well (25 µL/well). 
Lastly, 500 µL of cAMP-binding proteins (approximately 100 µg of crude extract from 
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bovine adrenal cortex) was added to each well. The deep-well plates were incubated on 
ice for 2 h and harvested with a Brandel cell harvester (Gaithersburg, MD) onto 
Whatman GF/B filters. Radioactivity bound to filters was quantified by liquid 
scintillation counting using a PerkinElmer Top Count. The concentration of cAMP in 
each well was calculated according to a cAMP standard curve ranging from 0.01 to 
1000 pM. 
 
Positive allosteric modulators of mGlu4 
 
Glutamate, histamine and N-Phenyl-7-(hydroxyimino)cyclopropa 
[b]chromen-1a-carboxamide (PHCCC) were purchased from Tocris Biosciences 
(Ellisville, Missouri). Acetylcholine was purchased from Sigma-Aldrich Incorporated (St. 
Louis, MO). cis-2-[[(3,5-Dichlorophenyl)amino]carbonyl]cyclohexanecarboxylic acid 
(VU0155041), N-(4-(N-(2-chlorophenyl)sulfamoyl)phenyl)picolinamide (4PAM-2), and 
5-methyl-N-(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2-amine (ADX88178) 
were synthesized in-house according to methods in (Celanire et al., 2011; Engers et al., 
2010; Niswender et al., 2008b; Reynolds, 2008). 
 
Astrocyte culture 
 
Rat cortical astrocytes were prepared using neocortices from 2-4 day old Sprague Dawley 
rats. Neocortics from pups were dissected and dissociated in DMEM by trituration and 
the cells were centrifuged and resuspended in growth media (DMEM supplemented with 
10 % FBS, 1 mM sodium pyruvate, 2 mM L-glutamine and antibiotics) in poly-D-lysine-
coated tissue culture dishes. Cells were maintained at 37 °C in an atmosphere of 95 % air/ 
5 % CO2 until ready for assay.  
 
Phosphoinositide hydrolysis assays using hippocampal slices 
Hippocampal slices were prepared according to the procedures described in (Ayala et al., 
2009). Following tissue recovery, the tissue was combined, washed with warm Krebs   
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buffer (108 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2.5 mM   CaCl2, 
25 mM NaHCO3 and 10 mM glucose), and 25 ml of gravity packed slices were incubated 
with 175 ml Krebs buffer containing 0.5 mCi  [3H]myo-inositol in 37ºC water bath for 45 
min. 10 mM LiCl was added to slices and incubated for an additional 15 min. Histamine 
and/or L-AP4 were then added, followed by 15 min incubation. Carbachol was used as 
positive control and Krebs buffer was used as negative control. The reaction was 
terminated and phosphoinositide was extracted, purified and quantified using liquid 
scintillation counting as previously described in (Ayala et al., 2009). 
 
Results 
 
Activation of histamine H1 receptor biases the signaling of mGlu4 toward calcium 
mobilization  
 
We have long been interested in the identification and characterization of small molecule 
positive allosteric modulators (PAMs) of mGlu4 for the symptomatic and disease 
modifying treatment of Parkinson’s disease. To characterize compounds, we employ a 
cell line in which the normally Gi/o-coupled mGlu4 is co-expressed with the chimeric G 
protein Gqi5 to permit induction of a calcium response downstream of mGlu4 activation, a 
technique that is commonly employed in high throughput screening campaigns for 
various 7TMRs as it is an easy and cost-effective method to measure compound activity. 
In addition to identifying small molecule allosteric modulators, we had designed parallel 
studies to explore the impact of endogenous neurotransmitters and ligands on the 
modulation of mGlu4 function. In the course of these studies, we discovered that 
application of the autacoid histamine to mGlu4-expressing cells, prior to application of a 
concentration of glutamate designed to induce a 20% maximal response, resulted in a 
strong potentiation of the calcium mobilization signal normally induced by glutamate in 
mGlu4/Gqi5-expressing cells. In these studies, the potentiation effect of histamine highly 
resembled the effects of synthetic PAMs of mGlu4, such as the prototype PAM N-Phenyl-
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7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC), with one important 
difference. While both histamine and PHCCC were able to potentiate the effects of an 
EC20 concentration of glutamate (Figure 2.1A and B, “Glutamate Add”), unlike PHCCC, 
histamine induced a weak response when added alone to mGlu4/Gqi5 cells (Figure 2.1B, 
“Compound Add”). In our experience using this mGlu4/Gqi5 assay, response of compound 
alone is not common. In Figures 2.1C and D, concentration-response curves are shown 
for the compound response in the absence and presence of an EC20 concentration of 
glutamate.  The control PAM PHCCC was inactive when added alone but exhibited a 
potency of 5.1±0.3 µM when potentiating the response to a low concentration of 
glutamate. In contrast, histamine generated a concentration-dependent response alone 
with a potency of 8.3±1.4 µM; in addition, histamine also potentiated the EC20 glutamate 
response (EC50=1.2±0.1 µM).  
 
Small molecule PAMs of mGlu4 have been shown to potentiate multiple responses 
downstream of mGlu4 activation (Jones et al., 2011; Niswender et al., 2008b). Therefore, 
if histamine directly binds to the mGlu4 protein and acts as a prototypical mGlu4 PAM, it 
would be expected to modulate additional, Gi/o-dependent pathways downstream of 
mGlu4 activation, such as cAMP inhibition. In contrast to our studies with calcium 
mobilization (Figure 2.1B, 2.1D and 2.2A), histamine did not potentiate the ability of 
mGlu4 activation to inhibit cAMP levels (Figure 2.2B). These results suggested that 
histamine induced biased signaling downstream of mGlu4 activation. It also indicated that 
the mechanism of histamine’s potentiation might differ from previously identified small 
molecule PAMs. 
 
While our previous results did not rule out the possibility that histamine directly 
interacted with mGlu4, the distinct signaling profile induced by histamine suggested that 
the mechanism of histamine’s potentiation might be due to activity at a site distinct from 
mGlu4, such as a histamine receptor. To determine if low levels of endogenous histamine 
receptors were involved in mediating the potentiation response, we performed RT-PCR 
experiments from our mGlu4-expressing cells and determined that they expressed low  
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Figure 2.1. Histamine differs from the small molecule mGlu4 PAM, PHCCC, in its 
potentiation effect. A and B, fluorescence traces of PHCCC and histamine in calcium 
mobilization assays measured in CHO-DHFR(-) cells co-expressing mGlu4 and the 
chimeric G protein Gqi5 in cells. PHCCC (A, ranging from 100 nM to 30 µM) or 
histamine (B, ranging from 100 nM to 100 µM) was added in the “Compound Add”, 
while an EC20 concentration of glutamate (2.5 µM final) was added after 150 sec in the 
“Glutamate Add”. C and D, Compound activity alone (Agonist Response) and PAM 
activity (PAM Response) in the presence of an EC20 concentration of glutamate (2.5 µM 
final) from traces represented in A and B are shown for PHCCC and histamine, 
respectively. For both responses, the increase in fluorescence units is normalized to the 
maximum response elicited by 1 mM glutamate in this cell line. PHCCC elicited no 
agonist response and possessed a potency of 5.1±0.3 µM for the PAM response. The 
potency of histamine for the PAM response was 1.2±0.4 µM and for the agonist response 
was and 8.3±1.4 µM. Data shown were performed in triplicate; Mean ± SEM.  
Histamine Traces
0 50 100 150 200
0.8
0.9
1.0
1.1
1.2
1.3
1.4
1.5 -4.0
-5.0
-5.5
-6.0
-6.5
-7.0
Compound
      Add
Glutamate
      Add
Time (seconds)
Fl
uo
re
sc
en
ce
 ra
tio
Histamine
-11 -10 -9 -8 -7 -6 -5 -4 -3
-25
25
75
125
175
Agonist Response
PAM Response
Log histamine, [M]
P
er
ce
nt
 M
ax
G
lu
ta
m
at
e 
R
es
po
ns
e
PHCCC
-10 -9 -8 -7 -6 -5 -4 -3
-25
25
75
125
175
225
275
PAM Response
Agonist Response
Log PHCCC, [M]
P
er
ce
nt
 M
ax
G
lu
ta
m
at
e 
R
es
po
ns
e
A B
C D
mGlu4/Gqi5/CHO-DHFR(-) cells
PHCCC Traces
0 50 100 150 200
0.8
0.9
1.0
1.1
1.2
1.3
1.4
1.5 -4.5
-5.0
-5.5
-6.0
-6.5
-7.0
Compound
      Add
Glutamate
      Add
Time (seconds)
Fl
uo
re
sc
en
ce
 ra
tio
	   36	  	  
 
 
 
Figure 2.2. Histamine potentiates calcium responses downstream of mGlu4 without 
impacting glutamate-dependent cAMP inhibition. A, Glutamate-induced calcium 
mobilization was measured in the presence of vehicle control (■) or 100 µM histamine 
(□). The responses are normalized to maximum effect of glutamate in the same cell line. 
Potencies in the absence or presence of 100 µM histamine were 5.1±0.9 µM vs. 2.0±0.3 
µM (*p=0.029; unpaired t-test). Maximal responses in the absence or presence of 100 
µM histamine were: 100.0±1.0% vs. 179.1±20.0% (*p=0.017; unpaired t-test). B, 
Glutamate-dependent intracellular cAMP concentration was quantified in the absence (■) 
or presence (□) of 100 µM histamine using a competitive binding assay as described in 
2.5. Adenylate cyclase assays. Data were normalized to the 20 µM forskolin-induced 
response. Potencies in the absence or presence of 100 µM histamine were 4.1±0.3µM vs. 
4.3±0.8µM (p=0.76; unpaired t-test). Maximal inhibition values in the absence or 
presence of 100 µM histamine were: 88.1±8.3% vs. 83.9±2.3% (p=0.65; unpaired t-test). 
Data shown were performed in triplicate; Mean ± SEM. Statistical analysis was 
performed using GraphPad Prism (La Jolla, CA). 
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levels of H1 histamine receptor mRNA (Figure 2.3A). PCR with primers against H2, H3 
and H4 receptor did not yield any specific bands to support the existence of other 
histamine receptors (Figure 2.4). To address the potential contribution of functional 
activity of Gq-coupled H1 receptors, we co-applied the H1 receptor antagonist 
mepyramine and 100 µM histamine to mGlu4-expressing cells in the first addition and  
then added an EC20 concentration of glutamate in the second addition. These studies 
revealed that mepyramine blocked the response induced by histamine application alone to 
a baseline level (Figure 2.3B), consistent with full blockade of H1. While mepyramine 
was also able to block the response induced by the glutamate EC20 addition, the blockade 
saturated at the level of the EC20 glutamate response (Figure 2.3B).  
 
These findings suggested that the potentiation effect was likely mediated by low levels of 
endogenous H1 protein present in our mGlu4 cell line. However, they did not completely 
rule out the possibility of direct histamine binding to mGlu4, since mepyramine might 
have exerted its effect by displacing binding of histamine from the mGlu4 receptor. 
Additionally, our original cell line contained the chimeric G protein Gqi5 to induce mGlu4-
mediated calcium mobilization, which would not be reflective of mGlu4 signaling in 
native tissues. In order to test the hypothesis that the potentiation effect was definitively 
mediated by H1 activity versus direct histamine interaction with mGlu4 and occurred in 
presence of native cellular G proteins, we screened a panel of cell lines to identify a line 
that did not express H1 mRNA. We found that CHO-K1 cells, in contrast to the CHO-
DHFR(-) cell background used for the initial screening, did not express H1 mRNA 
(Figure 2.3A). By utilizing the CHO-K1 cells as the parental cell line, we generated two 
new cell lines that contained either the mGlu4 receptor alone, or mGlu4 co-expressed with 
the H1 receptor; neither of these cell lines contained Gqi5. As shown in Figure 2.5A, 
mGlu4 was functional and coupled to glutamate-induced cAMP inhibition in cells 
expressing either mGlu4 alone or the mGlu4+H1 combination. We then performed studies 
in which we attempted to potentiate glutamate-induced calcium mobilization using 
increasing concentrations of histamine in cells without (Figure 2.5B) and with (Figure  
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Figure 2.3. The histamine H1 receptor may be involved in the potentiation effect of 
histamine. A, mRNA expression of histamine H1 receptor in different cell lines. mRNA 
was extracted from CHO-K1 cell line and mGlu4/Gqi5/CHO-DHFR(-) cell line and RT-
PCR was performed as described under Materials and Methods. “+RT” indicates 
presence of reverse transcriptase during the reaction of reverse transcription, whereas “–
RT” represents absence of reverse transcriptase as negative controls. Predicted size of the 
PCR product for the H1 receptor was 423 bp, as shown with arrow. B, Mepyramine 
abolishes the agonist response and potentiation effect of histamine. Increasing 
concentrations of mepyramine were added to mGlu4/Gqi5/CHO-DHFR(-) cells with 100 
µM histamine prior to addition of an EC20 concentration of glutamate (2.5 µM glutamate 
final). Calcium mobilization induced by the histamine addition and the subsequent 
glutamate addition was measured as described. Potencies of mepyramine in the histamine 
add or the glutamate add were: 1.55±0.5 µM vs. 393±154 nM (p=0.10; unpaired t-test). 
Data shown were performed in triplicate; Mean ± SEM. Statistical analysis was 
performed using GraphPad Prism (La Jolla, CA). 
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Figure 2.4. mRNA expression of histamine H2, H3 and H4 receptor (A-C 
respectively) in different cell lines. mRNA was extracted from different cell lines as 
labeled and RT-PCR was performed as described under Supplemental Methods. “+RT” 
indicates presence of reverse transcriptase during the reaction of reverse transcription, 
whereas “–RT” represents absence of reverse transcriptase as negative controls. Predicted 
size of PCR products for H2, H3 and H4 were 462 bp, 957 bp and 834 bp, respectively, as 
shown with arrows. 
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Figure 2.5. The histamine H1 receptor is required for the potentiation effect of 
histamine. A, Glutamate exhibits potencies of 1.0±0.03 µM and 2.3±0.1 µM, 
respectively, in adenylate cyclase assays in mGlu4/CHO-K1 cells and mGlu4/H1/CHO-K1 
cells (*p=0.0048, unpaired t-test). Intracellular cAMP concentration was measured as 
described in 2.5. Adenylate cyclase assays and responses were normalized to the 10 µM 
forskolin response in each cell line, respectively. B, The effect of 1 µM (▲), 10 µM (▼) 
and 100 µM (◆) histamine on glutamate-induced calcium mobilization in mGlu4/CHO-
K1 cells is shown. Maximal responses of vehicle, 1 µM, 10 µM or 100 µM histamine-
treated cells were 3391±1033, 3254± 841, 3067± 527 and 3214± 643 relative 
fluorescence units, respectively (p=0.99; One-way ANOVA). C, The effect of 30 nM (▲), 
100 nM (▼) and 300 nM (◆) histamine in potentiating calcium responses mediated by 
glutamate in mGluR4/H1/CHO-K1 cells is shown. Maximal responses in vehicle, 30 nM, 
100 nM or 300 nM histamine-treated cells were 1548±230, 3390±636, 10099±819, 
21261±1356 relative fluorescence units, respectively (*p<0.0001; One-way ANOVA). 
Data shown were performed in triplicate; Mean ± SEM. Statistical analysis was 
performed using GraphPad Prism (La Jolla, CA). 
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2.5C) H1. These results clearly showed that the potentiation required the presence of H1 
receptors. 
 
Concomitant activation of Gq coupled receptors pathway-selectively potentiate the 
calcium signaling of Gi-coupled receptors  
 
According to our findings, the potentiated calcium response that we observed was 
mediated by concomitant activation of the Gq-coupled H1 receptor and Gi/o-coupled 
mGlu4 receptor. We speculated that, if this potentiation was due to a signaling 
convergence, the phenomenon would extend to other Gq and Gi/o coupled receptor pairs. 
To test this hypothesis, we co-expressed mGlu4 with the muscarinic acetylcholine M1 
receptor, another Gq-coupled receptor which is also extensively expressed in the CNS. 
We observed that activation of the M1 receptor via acetylcholine in this mGlu4-co-
expressing cell line induced similar glutamate-dependent calcium mobilization compared 
to cells co-expressing H1 and mGlu4 (Figure 2.6A). We also hypothesized that such 
signaling crosstalk might be generalizable to other Gi/o-coupled mGlu receptors. As 
carried out for mGlu4, we constructed two mGlu2 cell lines in a CHO-K1 background, 
one of which expressed mGlu2 alone and the other in combination with H1 receptor. As 
shown in Figure 2.5B, cells expressing mGlu2 alone did not respond to histamine; in 
contrast, cells co-expressing H1 and mGlu2 exhibited robust potentiation of calcium 
responses after co-application of histamine and glutamate (Figure 2.6C). As shown 
previously (Rives et al., 2009), signaling of Gi/o and Gq receptors converges on the PLCβ 
pathway. To determine if this was also the mechanism of potentiated calcium responses 
for the receptors examined here, phosphoinositide hydrolysis assays were performed in 
cells co-expressing mGlu2 and H1 receptors. Consistent with our observations in calcium 
mobilization assays, histamine dramatically potentiated mGlu2-induced phosphoinositide 
hydrolysis (Figure 2.6D). 
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Functionally selective effects of mGlu4 positive allosteric modulators induced by co-
activation of H1 and mGlu4  
 
We are very interested in the development of small molecule positive allosteric 
modulators of mGlu4 and were particularly intrigued with our initial studies (Figure 2.2) 
that suggested that histamine may induce functionally selective activation of signaling 
pathways downstream of mGlu4. Furthermore, we hypothesized that co-application of 
histamine with mGlu4 PAMs could further selectively potentiate calcium responses 
compared to signaling induced by other Gi/o-dependent pathways. To evaluate this 
hypothesis, we used our generated mGlu4/H1/CHO-K1 cell line which does not express 
Gqi5. For these studies, we chose PAMs from four distinct chemical scaffolds (Celanire et 
al., 2011; Niswender et al., 2008b; Reynolds, 2008) (Figure 2.7). These compounds were 
chosen based on differential in vitro potency and efficacy at mGlu4; additionally, 
VU0155041 displays allosteric agonist activity in some assays (Niswender et al., 2008b) 
and has been proposed to bind to a different site on the mGlu4 receptor compared to 
PHCCC and 4PAM-2 (Drolet et al., 2011a). In these experiments, we added increasing 
concentrations of each PAM either alone or in combination with histamine in the first 
addition. As shown in Figure 2.8, addition of each PAM alone (white traces, 
“Compound/Histamine Add”) resulted in no calcium mobilization, even after glutamate 
addition (“Glutamate Add”). Addition of 300 nM histamine alone induced a relatively 
strong calcium response (dark gray traces); no potentiation of glutamate (second addition) 
was observed in this case due to the low concentration of glutamate added in these 
experiments. In contrast, addition of histamine + PHCCC, 4PAM-2, or ADX88178 
(Figure 2.8A, B, and C) resulted in a prolonged calcium transient after the first addition 
and a very strong potentiation of the glutamate addition. Consistent with its potential to 
display allosteric agonist activity in some assays, VU0155041 behaved differently from 
the other PAMs, and substantial potentiation was observed in the first addition when this 
compound was added with histamine (Figure 2.8D); in contrast, no further potentiation 
was observed during the glutamate addition. In Figure 2.9, the concentration-response 
curves for these compounds, plus and minus 100 nM and 300 nM histamine, are plotted  
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Figure 2.6. Phospholipase C pathway potentiation extends to additional Gq and Gi/o 
pairs. A, Acetylcholine (Ach) potentiates calcium responses induced by mGlu4 activation 
in mGlu4/M1/CHO-K1 cells. 3 nM Ach (□) or vehicle (■) control was added to cells in 
the first add, while increasing concentrations of glutamate were applied 150 sec later in 
the second add and calcium mobilization was measured. Maximal responses in the 
absence or presence of 3 nM Ach were: 2889±878 vs. 6175±280 relative fluorescence 
units (*p=0.024; unpaired t-test). Data shown were performed in triplicate; Mean ± SEM. 
B and C, histamine potentiates the calcium response of mGlu2 in the presence of the 
histamine H1 receptor in mGlu2/H1/CHO-K1 cells. In mGlu2/CHO-K1 cells, maximal 
responses in the absence or presence of 100 µM histamine were: 2072±23.7 vs. 
2122±272 relative fluorescence units (p=0.86; unpaired t-test). In mGlu2/H1/CHO-K1 
cells, maximal responses in the absence or presence of 1 µM histamine were: 2796±285 
vs. 8223±1128 relative fluorescence units (*p=0.010; unpaired t-test). Data shown were 
performed in triplicate; Mean ± SEM. D, Histamine potentiates mGlu2 responses in 
mGlu2/CHO-K1
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phosphoinositide hydrolysis assays in mGlu2/H1/CHO-K1 cells. Cells were treated with 
increasing concentrations of glutamate in the presence of 1 µM histamine (□) or vehicle 
control (■). After 1h incubation at 37℃, accumulated inositol phosphates were measured 
according to description in 2.4. Phosphoinositide hydrolysis assays. Maximal responses 
in the absence or presence of 1 µM histamine were: 6.9±1.8 vs. 68.7±5.8 cpm 
(*p=0.0005; unpaired t-test). Data from triplicate experiments are shown (Mean ± SEM) 
with relative baseline responses subtracted from each group. All Statistical analysis was 
performed using GraphPad Prism (La Jolla, CA).  
 
 
 
Figure 2.7. Chemical structures of mGlu4 PAMs used in these studies: PHCCC, 
4PAM-2, ADX88178 and VU0155041. 
PHCCC
VU0155041ADX88178
4PAM-­‐2
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Figure 2.8. Histamine dramatically potentiates the effect of PAMs on mGlu4-
mediated calcium mobilization in cells co-expressing mGlu4 and H1 receptors. Traces 
of calcium transients showing the effects of mGlu4 PAMs, histamine or the combination 
of both in potentiating the response of an EC20 concentration of glutamate (1 µM 
glutamate final) are shown. In these traces, a 10 µM concentration of each mGlu4 PAM 
(PHCCC, 4PAM-2, ADX88178 or VU0155041, in A-D respectively; (◊)), 300nM 
histamine (♦) or combination of both (♦) were applied in the first add 
(“Compound/Histamine Add”). After 150 sec, 1 µM glutamate (concentration determined 
based on cAMP experiments shown in Figure 5A) was applied in the second add 
(“Glutamate Add”). Calcium responses were measured as the fluorescence ratio, which 
involves dividing all fluorescence data for each point in the kinetic trace by the 
fluorescence value obtained in the first baseline sample read, which corrects for 
differences in dye loading and cell plating. 
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Figure 2.9. Histamine dose-dependently potentiates the efficacy of PAMs on mGlu4-
mediated calcium mobilization in cells co-expressing mGlu4 and H1 receptors. 
Results of traces in Figure 7 were plotted in concentration-response curve format. 
Increasing concentrations of the mGlu4 PAMs PHCCC, 4PAM-2, ADX88178 or 
VU0155041 (A-D, respectively) were applied either alone (■) or together with 100 nM 
(▲) or 300 nM (●) histamine in the first add. After 150 sec, a 1 µM glutamate 
concentration was applied in the second add. Calcium responses were measured as the 
fluorescence ratio, which involves dividing all fluorescence data for each point in the 
kinetic trace by the fluorescence value obtained in the first baseline sample read, which 
corrects for differences in dye loading and cell plating. Data were further normalized by 
taking the maximum calcium response minus the minimum response measured 3 seconds 
prior to either the first or second addition. For PHCCC (A), 4PAM-2 (B), and ADX88178 
(C) responses, the effect on the second addition (“Glutamate Add”) window is shown. 
For VU0155041 (D), the effect on the first addition (“Compound Add”) is shown. 
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Potencies for the different conditions were: PHCCC alone, no fit, PHCCC+100 nM 
histamine, 8.2±5.1 µM, PHCCC+300 nM histamine, 7.6±1.4 µM; 4PAM-2 alone, no fit, 
4PAM-2+100 nM histamine, 54.2±29.0 nM, 4PAM-2+300 nM histamine, 40.8±10.0 nM; 
ADX88178 alone, no fit, ADX88178+100 nM histamine, 37.2±15.1 nM, 
ADX88178+300 nM histamine, 30.0±5.2 nM; VU0155041 alone, no fit, 
VU0155041+100 nM histamine, 9.5±3.9 µM, VU0155041+300 nM histamine, 6.5±1.6 
µM. Maximal responses in the absence or presence of 100 nM or 300 nM histamine 
were: for PHCCC, 0.016±0.003, 0.089±0.010, 0.259±0.018 (*p<0.0001; One-way 
ANOVA); for 4PAM-2, 0.017±0.002, 0.212±0.013, 0.460±0.022 (*p<0.0001; One-way 
ANOVA); for ADX88178, 0.016±0.002, 0.197±0.003, 0.438±0.020 (*p<0.0001; One-
way ANOVA); and for VU0155041, 0.018±0.003, 0.221±0.032, 0.864±0.043 
(*p<0.0001; One-way ANOVA). Data shown were performed in triplicate; Mean ± SEM. 
Statistical analysis was performed using GraphPad Prism (La Jolla, CA). 
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Figure 2.10. In contrast to effects on calcium mobilization, histamine has no effect 
on the activity of mGlu4 PAMs in adenylate cyclase assays in cells expressing both 
mGlu4 and H1 receptors. Increasing concentration of mGlu4 PAMs (PHCCC, 4PAM-2, 
ADX88178 or VU0155041, A-D, respectively) were co-diluted with 1 µM glutamate and 
incubated with mGlu4/H1/CHO-K1 cells either alone or together with 300 nM histamine. 
Intracellular cAMP concentration was measured as described and then normalized to 
either 20 µM forskolin response or 20 µM forskolin+300nM histamine, respectively. 
Potencies in the absence or presence of 300 nM histamine were: PHCCC, 2.5±0.6 µM vs. 
1.8±0.4 µM (p=0.40; unpaired t-test); 4PAM-2, 55.5±12.6 nM v.s 66.1±8.6 nM (p=0.53; 
unpaired t-test); ADX88178, 11.7±2.0 nM vs. 16.0±4.3 nM (p=0.42; unpaired t-test); and 
VU0155041, 287.3±23.1 nM vs. 360.0±38.8 nM (p=0.18; unpaired t-test). Maximal 
inhibition values in the absence or presence of 300 nM histamine were: PHCCC, 
85.3±3.4% vs. 82.0±2.7% (p=0.49; unpaired t-test); 4PAM-2, 89.0±1.2 nM vs. 
89.4±0.6% (p=0.77; unpaired t-test); ADX88178, 90.4±1.5% vs. 91.1±0.6% (p=0.70; 
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unpaired t-test); and VU0155041, 89.5±0.4% vs. 90.0±0.1% (p=0.85; unpaired t-test). 
Data shown were performed in triplicate; Mean ± SEM. Statistical analysis was 
performed using GraphPad Prism (La Jolla, CA). 
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for the PAM (Figure 2.9A, B, and C) and agonist (Figure 2.9D) windows of the 
experiments shown in Figure 2.8; the responses to histamine in this assay are clearly 
concentration-dependent and the potencies of the PAMs obtained are consistent with the 
potencies observed in other assays (Celanire et al., 2011; Engers et al., 2010; Niswender 
et al., 2008b).  
 
In parallel experiments designed to test the potential for functional selectivity, we 
assessed the ability of histamine to affect cAMP inhibition responses induced by these 
PAMs in these same cells. For these studies, we performed concentration-response curves 
of these compounds, in the presence of an EC20 concentration of glutamate, with or 
without 300 nM histamine. Again, in contrast to calcium mobilization assays and as can 
be seen in Figure 2.10, histamine did not affect the cAMP responses to any of the PAMs 
tested. These results further suggest that co-activation/potentiation of the histamine H1 
receptor and mGlu4 results in functionally selective effects, resulting in unexpected 
calcium mobilization induced by mGlu4 PAMs. 
 
Exploration of H1-mGlu4 signaling crosstalk in native tissues 
 
Based on these interesting findings, we sought to explore the signaling crosstalk between 
H1 and mGlu4 using native tissues that coexpress the two receptors. It has been reported 
that the histamine H1 receptor is functionally expressed in astrocytes (Lipnik-Stangelj and 
Carman-Krzan, 2004a, b). mGlu4 levels have been reported to be very low in astrocytic 
cultures relative to mGlu5 (Peavy and Conn, 1998, J Neurochem, 71(2):603-612 and 
Besong et al., 2002, J Neurosci, 2213, 5403-5411). However, a low level of mGlu4 was 
detected in astrocytes by Besong et al, which was shown to be mediated astrocytic 
cytokine release (Besong et al., 2002). Therefore, primary rat cortical astrocyte cultures 
were prepared according to the method described in Besong et al (see Method for details) 
and evaluated in calcium assays. Consistent with previous studies, we performed 
immunoblot studies which revealed expression of mGlu4 monomers in astrocytes, but not 
mGlu4 dimers, the functional format of the receptor (Figure 2.11A). When tested in 
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calcium assays, we did not observe effects of mGlu4 activation on calcium mobilization 
or crosstalk between H1 and mGlu4 receptors, although histamine was able to induce 
profound calcium responses in these astrocytes (Figure 2.11B). We further explored the 
possibility of signaling crosstalk in hippocampal slices, where both receptors are 
expressed. 100 µM carbachol (Cch), a muscarinic agonist as a positive control, induced 
significant hydrolysis of phosphoinositide (Figure 2.11C). While 100 µM histamine 
triggered modest responses when added alone, this effect was not potentiated by co-
addition of 1 mM L-AP4 (Figure 2.11C), supporting an absence of signaling crosstalk in 
this brain region.  
 
Discussion 
 
In this chapter, we have explored the ability of convergent signaling to induce 
functionally selective effects downstream of allosteric modulation. These studies 
capitalized on initial reports, such as those of Rives et al. (Rives et al., 2009), showing 
that convergent signaling downstream of the Gi/o-coupled GABAB and Gq-coupled mGlu1 
receptors could result in potentiated calcium signaling. The effects reported in Rives et al. 
were apparent in transfected cells as well as in neurons, indicating that this potentiation 
can be observed in native tissues. We observed a similar interaction between mGlu4 and 
H1 histamine receptors in terms of calcium mobilization. In previous studies (Rives et al., 
2009), the mechanism for potentiation was a convergence of signaling via Gq G proteins 
and the Gβγ subunits of the Gi/o G protein at the level of PLCβ3. To explore the 
generalizability of this phenomenon for different mGlus, in addition to our mGlu4 and H1 
cells lines, we generated cells expressing mGlu4 and the Gq coupled M1 muscarinic 
receptor as well as cells co-expressing mGlu2 and H1. As shown in Figure 2.6, activation 
of the M1 receptor via acetylcholine in mGlu4-co-expressing cells induced similar 
glutamate-dependent calcium mobilization compared to cells co-expressing H1 and 
mGlu4. As shown for mGlu4, CHO-K1 cells expressing mGlu2 alone did not respond to  
	   52	  	  
Figure 2.11. Interaction of H1 receptor and mGlu4 was not detected in rat cortical 
astrocytes or hippocampal slices. A. expression of mGlu4 in rat cortical astrocytes were 
determined using Western blotting. Lanes from left to right: mGlu4/HEK/GIRK (positive 
control); HEK/GIRK (negative control); astrocytes from batch 1, day 6 after in vitro 
culture; astrocytes from batch 2, day 5 after in vitro culture. B. Agonist-induced 
responses were measured using calcium mobilization assay as described above. Vehicle 
or 100 nM, 1 µM, 3 µM and 10 µM histamine was added in the first add and serial 
dilutions of L-AP4 were added in the second add. Serial dilutions of histamine were used 
as positive control. C. Agonist-induced phosphoinositide hydrolysis was measured as 
described and the measured scintillation values were normalized to vehicle response (as 
0%), with 100 µM carbachol response as 100%.  
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histamine; in contrast, cells co-expressing H1 and mGlu2 exhibited robust potentiation of 
calcium responses when histamine and glutamate were co-applied. Finally, consistent  
with signaling that converges on the PLCβ pathway by co-activated Gi/o and Gq receptors 
(Rives et al., 2009), histamine dramatically potentiated mGlu2-induced phosphoinositide 
hydrolysis, suggesting that the potentiation mechanism we are observing here is similar. 
Since PLCβ can be activated by both Gαq and Gβγ subunit from the Gi G-protein, we 
propose that occupation of both might have a synergistic effect on IP3 production, 
inducing potentiated calcium mobilization. Indeed, mutagenesis studies of the PLCβ2 
protein have shown that distinct binding sites may exist for Gαq and Gβγ on the enzyme 
(Lee et al., 1993).  
 
The present studies extend previous observations by showing that the potentiation effect 
induced by Gq and Gi/o convergent activation is signaling pathway specific and does not 
extend to other Gi/o-mediated signaling events, such as cAMP inhibition. These findings 
suggest that this cascade convergence effectively results in functional selectivity at a 
signaling level. During the course of our development of mGlu4 PAMs, we have been 
interested in potential signaling bias or functionally selective effects induced by these 
compounds, particularly ligands belonging to different chemical scaffolds. In the assays 
we have examined, the majority of mGlu4 PAMs will potentiate multiple signaling 
pathways downstream of mGlu4 activation, including calcium mobilization induced using 
the chimeric G protein Gqi5 and GIRK channel activation (Jones et al., 2011; Niswender 
et al., 2008b), in addition to potentiation of cAMP inhibition as shown in this chapter. 
Our studies here show that the signal bias induced by histamine can be greatly potentiated 
in the presence of small molecule PAMs, with PAMs and histamine inducing dramatic 
potentiation of calcium responses versus other Gi/o-dependent responses. More 
importantly, our studies now show that PAMs with no ability to potentiate glutamate-
dependent calcium mobilization alone in the absence of chimeric G proteins (Figure 2.8, 
white traces) can induce substantial calcium signaling when the H1 receptor, and 
presumably other Gq coupled receptors, are co-activated (Figure 2.8,black traces). 
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This unmasking of a substantial calcium response could be highly important in the 
physiological effects induced by PAMs in vivo. While the H1 receptor and mGlu4 do 
exhibit different expression patterns in neurons (for example, mGlu4 is predominantly 
presynaptic and H1 predominantly postsynaptic), which may account for the absence of 
crosstalk in hippocampal slices (Figure 2.11C), there are locations where their expression 
may overlap, such as dendritic cells of the immune system (Fallarino et al., 2010; 
Vanbervliet et al., 2011). Additionally, the observations that signaling convergence can 
extend to other receptor pairs suggests that it is highly likely that there are locations in 
which Gq and Gi/o receptors may co-localize. In particular, mGlu2 is expressed in many 
postsynaptic neurons (Neki et al., 1996; Petralia et al., 1996) and mGlu2 PAMs are 
currently being developed for schizophrenia treatment, suggesting that a similar 
phenomenon may also impact mGlu2 PAM signaling in postsynaptic neurons.    
 
Another interesting point of speculation is that the strategy outlined here might provide a 
viable mechanism to potentiate the signaling of an intractable target. For example, there 
is substantial evidence indicating that activation of H1 in neurons may have beneficial 
effects in terms of attention and wakefulness (reviewed in (Thakkar, 2011)). Due to the 
substantial expression of H1 in various immune system cells, however, it would be 
difficult to pursue direct H1 agonists or PAMs as drugs for attention without inducing 
substantial adverse effects. Exploiting the activity of a convergent signaling partner, 
however, might be an alternate mechanism by which to increase signaling of a Gq 
coupled 7TMR that is difficult to modulate directly. While mGlu4 expression in dendritic 
cells of the immune system may preclude it as a strategy to potentiate H1 signaling, 
restricted postsynaptic neuronal expression of other Gi/o-coupled receptors that are not 
expressed in immune cells could be an interesting strategy to explore. 
 
In conclusion, we have shown that co-activation of mGlu4 and the H1 histamine receptor 
induces strong potentiation of calcium mobilization but not traditional Gi/o signaling 
pathways, indicating functional selectivity in signal transduction. These functionally 
selective effects are observed in the absence of chimeric or promiscuous G proteins and 
are synergistically potentiated in the presence of small molecule PAMs. Finally, these 
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studies reveal that signaling events induced by PAMs may be “unmasked” in the 
presence of convergent signaling by Gq coupled receptors, which may lead to complex 
and unexpected pharmacology. The concept of functional selectivity may be the next 
frontier in the translation of novel therapeutics into patient populations, and it is 
anticipated that further exploration of compound pharmacology will certainly aid in the 
understanding of therapeutic efficacy and adverse effects. 	    
	   56	  	  
CHAPTER III 
 
HETERODIMERISATION OF MGLU2/4 DIFFERENTIALLY REGULATE 
EFFECT OF ALLOSTERIC MODULATORS 
 
Introducton 
 
The metabotropic glutamate (mGlu) receptors are members of the Family C Seven 
Transmembrane Spanning/G Protein Coupled Receptors (7TMRs/GPCRs) and are 
activated by the major excitatory neurotransmitter, glutamate. In their simplest context, 
Group I mGlus (mGlu1 and mGlu5) primarily modulate postsynaptic neuronal activity, 
whereas the Group II mGlus (mGlu2 and mGlu3) are found in both presynaptic and 
postsynaptic locations, and the Group III receptors  (mGlu4, 6, 7, and 8) are predominantly 
expressed presynaptically, where they act as auto- and heteroreceptors to regulate  
neurotransmitter release (reviewed in (Niswender and Conn, 2010)).  The eight mGlu 
receptor subtypes have been historically thought to function as homodimers (Kunishima 
et al., 2000; Romano et al., 1996). However, recent in vitro studies suggest that mGlu 
receptors can also form heterodimers (Doumazane et al., 2011a; Kammermeier, 2012) 
with group I mGlus interacting with each other but not associating with other subtypes, 
and members of group II and III receptors co-assembling in vitro. 
 
Among the group III mGlu receptors, mGlu4 plays an important role in the basal ganglia, 
a primary site of pathology in movement disorders such as Parkinson’s disease (PD). 
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Activation of mGlu4 reduces transmission at synapses that project from the striatum to 
the globus pallidus (striatopallidal synapses) as well as synapses between the subthalamic 
nucleus and the substantia nigra pars compacta (STN-SNc synapses (Marino et al., 2003; 
Valenti et al., 2005; Valenti et al., 2003)), two synapses that are overactive in PD. At 
each of these synapses, the response to the general group III mGlu agonist L-AP4 is 
potentiated by PHCCC (Marino et al., 2003; Valenti et al., 2005), a positive allosteric 
modulator (PAM) that is selective for mGlu4.  In contrast to findings at the striatopallidal 
and STN-SNc synapses, we now report the surprising observation that PHCCC is without 
effect in regulating mGlu4-modulated transmission at corticostriatal synapses. 
 
Previous immunohistochemistry and in situ hybridization studies suggest that mGlu2 and 
mGlu4 are co-localized in several brain regions (Bradley et al., 1999; Neki et al., 1996; 
Ohishi et al., 1995; Ohishi et al., 1993) and mGlu2 is also functionally expressed at 
corticostriatal synapses (Johnson et al., 2005).  We tested the hypothesis that 
heterodimers of mGlu2/4 may display a unique profile in response to selective mGlu4 
PAMs and that these mGlu subtypes would form hetero-complexes in the striatum. 
Through evaluation of mGlu4 PAMs from different chemical scaffolds, we show here that 
hetero-interactions between mGlu2 and mGlu4 differentially impact responses to 
individual mGlu receptor PAMs and an mGlu2 negative allosteric modulator (NAM). 
Furthermore, co-immunoprecipitation studies suggest that mGlu2 and mGlu4 receptors 
form hetero-complexes in the striatum and the unique pharmacological profile of effects 
of selected mGlu4 receptor PAMs, as well as an mGlu2 NAM, is recapitulated at the 
corticostriatal synapse. These studies directly impact our understanding of mGlu 
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receptors and regulation by allosteric modulators in the basal ganglia and provide critical 
insights into potential functions and pharmacological properties of mGlu receptors that 
are co-expressed in multiple other regions and cell populations. 
 
Methods 
 
Cell line establishment and cell culture  
 
Cell culture reagents were purchased from Life Technologies (Carlsbad, CA) unless 
otherwise noted. Rat mGlu2 or rat mGlu4 were cloned into the pIRESpuro3 vector, 
transfected into HEK/GIRK cells and selected with puromycin. Polyclonal rat 
mGlu2/HEK/GIRK and rat mGlu4/HEK/GIRK cells were cultured in growth media as 
previously described in (Niswender et al., 2008a), supplemented with Non-Essential 
Amino Acids. Rat mGlu4 was also subcloned into the pIREShyg3 vector and the resulting 
plasmid was transfected into rat mGlu2/HEK/GIRK cells; cells were then selected with 
200 µg/mL hygromycin B. Polyclonal cells were cultured in growth media supplemented 
with 100 µg/ml hygromycin B.  
 
Western blot analysis 
 
Cells were scraped into lysis buffer (50 mM Tris·HCl, pH 7.5, 150mM NaCl, 0.5% 
Nonidet P40 and 0.5% Deoxycholate) containing protease inhibitor cocktail (Roche, 
Indianapolis, IN) and incubated on ice for 20-30 min. The supernatant was separated 
from cell debris by centrifugation at 16,000×g for 10 min at 4°C. Protein concentrations 
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in cell lysates were quantified by Bio-Rad Protein Assay (Bio-Rad, Hercules, CA) or 
Bradford protein assay (Bio-Rad) and aliquots of lysate were heated in SDS sample 
buffer (containing 10% SDS and 9.3% DTT) at 65°C for 5 min. Samples were loaded to 
SDS–polyacrylamide gel for electrophoresis and transferred to nitrocellulose membranes 
(Bio-Rad). After transfer, membranes were blocked in TBST (25mM Tris, 150mM NaCl 
and 0.05% Tween-20) containing 5% non-fat milk at room temperature for 1 h. mGlu2 
antibodies (Advanced Targeting Systems, San Diego, CA, cat # AB-N32) and mGlu4a 
antibodies (Upstate, Billerica, MA, cat # 06-765) were diluted in blocking solution and 
incubated with the membranes at 4°C overnight. Membranes were then washed with 
TBST and incubated with horseradish peroxidase-conjugated goat anti-mouse IgG 
secondary antibody (Santa Cruz, Santa Cruz, CA, cat # sc-2060, 1:7,500 diluted in 
blocking buffer (Jackson ImmunoResearch, West Grove, PA, cat # 115-035-166, 
1:10,000 diluted in blocking buffer) for mGlu2 or horseradish peroxidase-conjugated goat 
anti-rabbit IgG secondary antibody (Santa Cruz, Santa Cruz, CA, cat # sc-2004, 1:7,500 
diluted in blocking buffer or Jackson ImmunoResearch, West Grove, PA, cat # 111-035-
144, 1:10,000 diluted in blocking buffer) for mGlu4 at room temperature for 1 h. 
Membranes were washed again with TBST and an enhanced chemiluminescent assay 
(Thermo Scientific, Waltham, MA, cat # 32106 or 34075) was performed to detect 
immunoreactive proteins. 
 
Co-immunoprecipitation 
 
In cell line experiments, mGlu2/HEK/GIRK, mGlu4/HEK/GIRK and mGlu2/4/HEK/GIRK 
cells were lysed with IP lysis buffer (50 mM Tris·HCl, pH 7.5, 150mM NaCl, 2mM 
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EDTA, 1% Nonidet P40 with Complete Mini protease inhibitor cocktail (Roche, Basel, 
Switzerland, cat # 04693159001)) for IP experiments using the mGlu4 antibody; buffer 
was supplemented with 0.5% sodium deoxycholate for experiments using the mGlu2 
antibody.  Cell lysates were passed through G27 needles and incubated on ice for 30 min. 
The supernatant was centrifuged and pre-cleared with protein A/G beads (Santa Cruz, sc-
2003) at 4°C for 2-3 h. mGlu2- (Advanced Targeting Systems, San Diego, CA, cat # AB-
N32) or mGlu4 (Upstate, Billerica, MA, cat # 06-765) antibodies were bound to protein 
A/G beads by rotating at 4°C for 2-3 h. Pre-cleared cell lysates were then added to 
antibody-bound protein A/G beads or to beads without antibody as a negative control. 
After overnight rotation at 4°C, the beads were washed 3 times with washing buffer (IP 
lysis buffer without EDTA or protease inhibitors) and pelleted by low-speed 
centrifugation. SDS sample buffer was added to elute bound proteins. Samples were 
heated at 65°C for 5 min and subjected to SDS-PAGE and western blot analysis.  
 
For co-immunoprecipitation assays in rat or mouse brain samples, Sprague Dawley rats 
of mixed gender (Charles River, Wilmington, MA) and ICR(CD-1) or male mice (Harlan, 
Indianapolis, IN) 22-30 days old were anesthetized under isoflurane anesthesia, 
decapitated, and brains were rapidly removed and cut into 0.5-1 mm coronal slices using 
a brain matrix or a vibratome (Leica, Buffalo Grove, IL). Slices were transferred to a 
chilled metal surface and dorsal striatum and medial prefrontal cortex (prelimbic and 
infralimbic regions) were dissected using a scalpel blade and immediately frozen on dry 
ice. Samples were homogenized in buffer containing  (in mM): 50 Tris HCl, pH 7.4, 50 
NaCl, 10 EGTA, 5 EDTA, 2 NaF, 1 Na3VO4, 1 PMSF supplemented with 1× Complete 
	   61	  	  
Mini protease inhibitor cocktail, phosphatase inhibitor cocktails 2 and 3 (Sigma-Aldrich, 
St. Louis, MO). Homogenized samples were centrifuged at 16,100×g for 15 min at 4 °C 
and pelleted membranes were stored at -80°C. Membrane pellets were resuspended in IP 
lysis buffer (same as IP lysis buffer for IP mGlu4 in cell lines, supplemented with 1mM 
PMSF) and nutated at 4°C for 1 h. Supernatant was prepared by centrifugation at 
16,100×g for 15 min and pre-cleared by protein A/G beads at 4°C for 2-3 h. mGlu4 
antibodies or normal rabbit IgG (Millipore, Billerica, MA, cat# 12-370) were bound to 
protein A/G beads by rotating at 4°C for 2-3 h. Pre-cleared cell lysates were then added 
to mGlu4 antibody bound protein A/G beads or rabbit IgG-coupled beads as a negative 
control. After overnight rotation at 4°C, the beads were washed and samples were eluted 
and analyzed as described above.  
 
Thallium flux assays 
Thallium flux assays were performed according to methods described in (Niswender et 
al., 2008b) with minor modifications. For dye loading, media was exchanged with Assay 
Buffer (Hanks Balanced Salt Solution (HBSS) containing 20mM HEPES, pH 7.4) using 
an ELX405 microplate washer (BioTek), leaving 20 µL/well, followed by addition of 20 
µL/well 2× FluoZin-2 AM (330 nM final) indicator dye (Life Technologies, prepared as a 
DMSO stock and mixed in a 1:1 ratio with pluronic acid F-127) in Assay Buffer. After a 
1 h incubation at room temperature, dye was exchanged with Assay Buffer, leaving 20 
µL/well. Thallium flux was measured at room temperature using a Functional Drug 
Screening System 7000 (FDSS 7000, Hamamatsu). Baseline readings were taken (2 
images at 1 Hz; excitation, 470 ± 20 nm; emission, 540 ± 30 nm), and test compounds 
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(2×) were added in a 20 µL volume and incubated for 140s before the addition of 10 µL 
of Thallium Buffer with or without agonist (5×). Data were collected for an additional 2.5 
min and analyzed using Excel (Microsoft Corp, Redmond, WA) as previously described 
(Niswender et al., 2008b), and the concentration-response curves were fitted to a four-
parameter logistic equation to determine potency estimates using GraphPad Prism: 
𝑦 = 𝑏𝑜𝑡𝑡𝑜𝑚 + 𝑡𝑜𝑝 − 𝑏𝑜𝑡𝑡𝑜𝑚1+ 10 !"#$%!"!! !"##$#%&' 
where A is the molar concentration of the compound; bottom and top  denote the lower 
and upper plateaus of the concentration-response curve; HillSlope is the Hill coefficient 
that describes the steepness of the curve; and EC50 is the molar concentration of 
compound required to generate a response halfway between the top and bottom. 
 
Operational modeling of allosterism 
 
Shifts of agonist concentration-response curves by allosteric modulators were globally 
fitted to an operational model of allosterism (Leach et al., 2007): 
𝑦 = 𝑏𝑎𝑠𝑎𝑙 + (!!!!"#"$)(!! ! !!!!" ! !!! ! !!)!!![!](!!!!! ! !!! ! !!)!!( ! !!!!!!!!!! ! !! ! ! )!  
where A is the molar concentration of the orthosteric agonist; B is the molar concentration 
of the allosteric modulator; KA is the equilibrium dissociation constant of the orthosteric 
agonist, and KB is the equilibrium dissociation constant of allosteric modulator. Affinity 
modulation is governed by the cooperativity factor α, and efficacy modulation is 
governed by β. The parameters τA and τB relate to the ability of orthosteric agonist and 
allosteric ligands, respectively, to directly activate the receptor. Basal, Em and n represent 
	   63	  	  
the basal system response, maximal possible system response and the transducer function 
that links occupancy to response.  
 
Alternatively, a simplified version of this model was applied to estimate a composite 
cooperativity parameter (αβ) for PAMs (Leach et al., 2007): 𝑦 = 𝑏𝑎𝑠𝑎𝑙 + (!!!!"#"$)(!! ! !!!!" ! !!! ! !!)!!![!](!!!!" ! !!! ! !!)!!(!! !!! ! )!     
where all parameters are as described above.  
 
For the simulation of mGlu4 PAM effects, the logKA of L-AP4 for mGlu4 was set to -
6.759 according to literature values (Monastyrskaia et al., 1999), and was assumed to be 
unaltered at mGlu2/4 heterocomplexes.  For PHCCC and 4PAM-2, logτB was set to -100 
due to the lack of allosteric agonist activity but was allowed to float for compounds 
exhibiting allosteric agonism (VU0155041, Lu-AF29134). For the simulation of MNI-
137, the logKA of DCG-IV for mGlu2 was set to -6.959 according to literature values 
(Schweitzer et al., 2000), and was assumed to be unaltered at mGlu2/4 heterocomplexes; 
logτB was set to -100. 
 
Transient transfections 
 
Two days before the assay, combinations of pIRES-hyg3-rat mGlu2, pIRES-hyg3-rat 
mGlu4, and pIRES-hyg3-rat mGlu7 were co-transfected with ratios of 0 µg:1 µg, 0.1 µg:1 
µg, 0.2 µg:1 µg, 0.5 µg:1µg or 1 µg:1µg of DNA into HEK/GIRK cells using Fugene 6 
(Promega, Fitchburg, WI) according to the manufacturer’s protocol. After 24 hours, cells 
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were trypsinized and plated in 384-well poly D-lysine-coated plates using assay media. 
Plates were then tested the next day using the thallium flux assay as described above.  
 
Whole-cell patch-clamp recordings 
 
Whole-cell patch-clamp recordings were performed using coronal slices prepared from 
15- to 19-day-old Sprague-Dawley rats of mixed gender (Charles River, Wilmington, 
MA). Animals were anesthetized with isoflurane and brains were removed and 
submerged into ice-cold cutting solution (in mM: 220 sucrose, 2.5 KCl, 1.25 NaH2PO4, 
26.2 NaHCO3, 10 D-glucose, 0.5 CaCl2, 8 MgCl2).  Coronal slices containing the 
striatum were cut at 300 µm using a vibratome (Leica VT 1200S) or a compresstome 
(Precisionary Instruments, Greenville, NC).  Slices were transferred to a holding chamber 
containing ACSF (in mM: 126 NaCl, 2.5 KCl, 1.2 NaH2PO4, 25 NaHCO3, 11 D-glucose, 
2.4 CaCl2, 1.2 MgCl2) supplemented with 5 µM glutathione, for slice viability, for 25 min 
at 32°C. All buffers were continuously bubbled with 95% O2/5% CO2. Subsequently, 
slices were maintained at room temperature for at least 30 minutes in ACSF, then 
transferred to a submersion recording chamber where they were perfused with room 
temperature ACSF at a rate of 2 ml/min. Neurons were visualized with a 40× water 
immersion lens with Hoffman modulation contrast optics coupled with an Olympus 
BX50WI upright microscope (Olympus, Lake Success, NY). Borosilicate glass patch 
electrodes were pulled using a Flaming/Brown micropipette puller (Sutter Instruments, 
CA) and had a resistance of 4-6 MΩ when filled with an intracellular solution containing 
(in mM: 123 potassium gluconate, 7 KCl, 0.025 CaCl2, 1 MgCl2, 10 HEPES, 0.1 EGTA, 
2 magnesium-ATP, 0.2 sodium-GTP; pH adjusted to 7.3 with 1 N KOH; 295 mOsm).  
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Whole-cell recordings were made from medium spiny neurons which were visually 
identified and then confirmed by determining the current-voltage relationship of positive 
or negative current injections; a MultiClamp 700B amplifier (Molecular Devices, 
Sunnyvale, CA) was used for current-clamp recordings. Data were digitized with a 
DigiData 1331 system (Molecular Devices, Sunnyvale, CA) and acquired using 
pClamp10.2 (Molecular Devices, Sunnyvale, CA). EPSPs were evoked in medium spiny 
neurons by placing a bipolar electrode in the white matter between the cortex and 
striatum. After formation of a whole-cell configuration, membrane potential was recorded 
and current was injected to maintain resting membrane potential at -75 mV and changes 
in membrane potential were recorded. Compounds were diluted in ACSF and bath 
applied as noted. Data were analyzed using Clampfit 10.2 (Molecular Devices, Sunnyvale, 
CA).  
 
Drugs 
 
Glutamate, DCG-IV, CBiPES and LY487379 was purchased from Tocris Biosciences 
(Ellisville, Missouri). L-AP4, LY379268 and N-Phenyl-7-
(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC) were purchased from 
Abcam Biochemicals (Cambridge, UK).  cis-2-[[(3,5-
Dichlorophenyl)amino]carbonyl]cyclohexanecarboxylic acid (VU0155041), N-(4-(N-(2-
chlorophenyl)sulfamoyl)phenyl)picolinamide (4PAM-2), (1S,2R)-N1-(3,4-
dichlorophenyl)cyclohexane-1,2-dicarboxamide (Lu AF21934) and biphenylindanone A 
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(BINA) were synthesized in-house. Synthesis of VU0155041, BINA, and MNI-137 was 
performed according to methods in the following references: (Galici et al., 2006; 
Hemstapat et al., 2007; Niswender et al., 2008b).  
 
Synthesis of 4PAM-2 and Lu AF21934 was performed according to methods described 
below: 
 
General. All NMR spectra were recorded on a 400 MHz AMX Bruker NMR 
spectrometer.  1H chemical shifts are reported in δ values in ppm downfield with the 
deuterated solvent as the internal standard.  Data are reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), 
integration, coupling constant (Hz). Low resolution mass spectra were obtained on an 
Agilent 1200 series 6130 mass spectrometer with electrospray ionization.  High 
resolution mass spectra were recorded on a Waters Q-TOF API-US plus Acquity system 
with electrospray ionization.  Analytical thin layer chromatography was performed on 
EM Reagent 0.25 mm silica gel 60-F plates.  Analytical HPLC was performed on an 
Agilent 1200 series with UV detection at 214 nm and 254 nm along with ELSD detection.  
LC/MS: Restek-C18, 3.2x30mm, 2 min gradient, 
10%[0.05%TFA/CH3CN]:90%[0.05%TFA/H2O] to 100%[0.1%TFA/CH3CN] or 
Phenomenex-C18, 2.1 X 30 mm, 1 min gradient, 
7%[0.1%TFA/CH3CN]:93%[0.1%TFA/H2O] to 95%[0.1%TFA/CH3CN].   Preparative 
purification was performed on a custom HP1100 purification system with collection 
triggered by mass detection.  Solvents for extraction, washing and chromatography were 
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HPLC grade.   All reagents were purchased from Aldrich Chemical Co. and were used 
without purification.    
4PAM-2 (N-(4-(N-(2-chlorophenyl)sulfamoyl)phenyl)picolinamide): 
 
To a solution of 2-chloroaniline (0.95 mL, 9.02 mmol, 1.0 eq) in pyridine (5 mL) and 
DCM (5 mL) at 0°C was added 4-nitrobenzenesulfonylchloride (2.0g, 9.02 mmol, 1.0eq).  
After 15 min, the cold bath was removed.  After an additional 24 h at rt, the rxn was 
added to 1N HCl (aq) (50 mL) and DCM (50 mL).  The organic layer was separated, 
washed with 1N HCl (aq) (20 mL), H2O (2 x 20 mL), brine (20 mL) and dried (MgSO4).  
The mixture was filtered and concentrated to afford 1 (2.73g, 97%).  The residue was 
carried through without further purification. 
Rf  0.85 (50% EtOAc/hexanes); 
LCMS: Rt=1.403 min, M+H=313.0; >98% @ 215 and 254 nm 
1H NMR (400 MHz, CDCl3): δ 8.27 (d, J = 9.0 Hz, 2H), 7.92 (d, J = 9.0 Hz, 2H), 7.70 
(dd, J = 8.1, 1.4 Hz, 1H), 7.32-7.26 (m, 2H), 7.13 (ddd, J = 8.8, 8.8, 1.5 Hz, 1H), 7.01 (br 
s, 1H) 
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To a solution of 1 (2.73g, 8.73 mmol, 1.0eq) in EtOAc (40 mL) was added 5% Pd/C 
(~150 mg).  The rxn atmosphere was evacuated and purged with H2 balloon (1 atm).  The 
rxn was followed by TLC.  After 4h, the rxn mixture was filtered through Celite and 
concentrated to provide a white solid (2.45g, 99%). 
Rf  0.50 (50% EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3): δ 7.64 (dd, J = 8.2, 1.4 Hz, 1H), 7.54 (d, J = 8.7 Hz, 2H), 
7.24-7.19 (m, 2H), 7.01 (ddd, J = 7.8, 7.8, 1.5 Hz, 1H), 6.91 (br s, 1H), 6.58 (d, J = 8.8 
Hz, 2H), 4.11 (br s, 2H) 
 
To a solution of 2 (2.45g, 8.66 mmol, 1.0eq) in DMF (16 mL) and Hunig’s Base (3.64 
mL, 25.98 mmol, 3.0eq) at 0°C was added picolinoyl chloride hydrochloride (1.70g, 9.53 
mmol, 1.1eq).  After 15 min, the ice bath was removed.  After an additional 24h at rt, the 
rxn was added to EtOAc:H2O (1:1, 100 mL).  The organic layer was separated and 
washed with H2O (2 x 50 mL), brine (50 mL), dried (MgSO4) and concentrated. The 
residue was purified by reverse phase liquid column chromatography (40-80% 
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acetonitrile: H2O with 0.1% trifluoroacetic acid).  The collected fractions were added to 
EtOAc:NaHCO3(aq) (1:1, 100 mL).  The organic layer was separated and washed with 
H2O (50 mL), brine (50 mL), dried (MgSO4), filtered and concentrated to afford a white 
solid.  The white solid was dissolved in DCM (25 mL) and 4N HCl in dioxane (5 mL) 
was added.  After 5 min, the solvent was removed to yield 4PAM-2 as an HCl salt (1.06 
g, 32% yield). 
LCMS: Rt=1.455 min, M+H=387.8; >98% @ 215 and 254 nm 
1H NMR (400 MHz, d-DMSO): δ 11.01 (s, 1H), 9.92 (s, 1H), 8.77 (d, J = 4.2 Hz, 1H), 
8.18 (d, J = 7.6 Hz, 1H), 8.10 (d, J = 8.7 Hz, 2H), 8.09-8.08 (m, 1H), 7.73-7.71 (m, 1H), 
7.71 (d, J = 8.8 Hz, 2H), 7.41 (dd, J = 7.8, 1.2 Hz, 1H), 7.32-7.26 (m, 2H), 7.23-7.19 (m, 
1H); 
HRMS, calc’d for C18H14N3O3NaSCl (M+Na+), 410.0342; found 410.0339. 
Lu AF21934 (N1-(3,4-dichlorophenyl)cyclohexane-1,2-dicarboxamide): 
 
 
Into a 50 mL round bottom flask, containing a magnetic stir bar, was weighed 1.3751 
mmol (212 mg) of cyclohexyldicarboxylic anhydride (predominantly cis) followed by 6 
mL chloroform. To this solution was added 0.9167 mmol (148.5 mg) of 3,4-
dichloroaniline. After being fitted with a reflux column the reaction mixture was heated 
in an oil bath to reflux at 70°C for 2 h, with magnetic stirring. Over this time a white 
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solid crashed out of the reaction mixture. After cooling the reaction to ambient 
temperature, the solid was isolated via vacuum filtration and washed with cold 
chloroform to obtain 434.8 mg of the desired product, 3 (78.4% yield) as a crystalline 
white powder.  
LCMS: Rt= 0.741 min, M+H=315.7; >98% @ 215 and 254 nm; 
HRMS calcd for C14H15Cl2NO3[M+H]: 315.0667 found 315.0668;  
1H NMR (400 MHz, methyl sulfoxide-d6 calibrated to 2.54) δ10.02 (s, 1H), 7.99 (d, J = 
2.39 Hz, 1H), 7.53 (d, J = 8.79 Hz, 1H), 7.46 (dd, J = 8.87, 2.43 Hz, 1H),  2.92 (q, J = 
4.78 Hz, 1H), 2.64-2.60 (m, 1H), 2.12-2.03 (m, 1H), 1.99-1.94 (m, 1H), 1.76-1.61 (m, 
3H), 1.41-1.29 (m, 3H).  
 
To a 4 mL vial were weighed 0.3115 mmol (98.5 mg) compound 3, 0.9345 mmol (98.5 
mg) ammonium chloride, 0.3738 mmol (71.5 mg) 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide, and 0.3115 mmol (42.1 mg) hydroxybenzotriazole, 
followed by 3 mL of 9:1 dimethylformamide:diisopropylethylamine. The reaction vial 
was rotated at room temperature overnight. The reaction was diluted with ethyl acetate 
(~5 mL) and washed with brine. The organic phase was separated and dried over sodium 
sulfate. Solvent was removed under reduced pressure and the crude product was purified 
via flash column chromatography. Product-containing fractions were combined and the 
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solvents removed under reduced pressure to obtain 31 mg of the desired product, Lu 
AF21934 (31.5% yield) as an off-white powder.  
LCMS: 0.690 min, M+H=314.7; >98% @ 215 and 254 nm; 
HRMS calcd for C14H16Cl2N2O2[M+H]: 316.0507 found 316.0507;  
1H NMR (400 MHz, methyl sulfoxide-d6 calibrated to 2.54): δ9.92 (s, 1H), 8.01 (d, J = 
2.27 Hz, 1H), 7.51 (d, J = 8.91 Hz, 1H), 7.44 (dd, J = 8.88, 2.42, 1H), 7.06 (s, 1H), 6.72 
(s, 1H), 2.80 (q, J = 4.83 Hz, 1H), 2.50-2.46 (m, 1H), 2.15-1.98 (m, 1H), 1.70-1.48 (m, 
1H), 1.39-1.23 (m, 1H). 
 
Animal studies 
 
Animals were maintained in accordance with the guidelines of the American Association 
for the Accreditation of Laboratory Animal Care under a 12 hour light/dark cycle (lights 
on 06:00 to 18:00) with free access to food and water. All experiments were approved by 
Vanderbilt University’s Institutional Animal Care and Use Committee, and conformed to 
guidelines established by the National Research Council Guide for the Care and Use of 
Laboratory Animals. All efforts were made to minimize animal suffering and the number 
of animals used. 
 
Statistical analysis 
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All data shown represent Mean±SEM value for at least three replicates. Statistical 
significance between groups was determined using unpaired Student’s t tests or ANOVA 
(with Dunnett’s or Bonferroni’s post-test) as specified in each Figure Legend. 
 
Results 
 
mGlu4 interacts with mGlu2 to form heterocomplexes both in vitro and in brain 
tissue 
 
PHCCC is the first described mGlu4 positive allosteric modulator (PAM) (Maj et al., 
2003; Marino et al., 2003) and has been used to probe the activity of mGlu4 at various 
synapses in the basal ganglia and other brain regions (Jones et al., 2008; Marino et al., 
2003; Valenti et al., 2005). The efficacy of PHCCC at striatopallidal and STN-SNc 
synapses is consistent with its symptomatic and disease modifying effects in PD animal 
models (Battaglia et al., 2006; Marino et al., 2003). In addition to striatopallidal and 
STN-SNc synapses, immunohistochemistry studies reveal that mGlu4 is expressed at 
corticostriatal synapses, which represent the primary input to the basal ganglia from the 
motor cortex (Corti et al., 2002).  Consistent with expression studies, Bennouar et al. 
recently reported that the mGlu4 PAM Lu AF21934 reduces corticostriatal transmission 
(Bennouar et al., 2012). To further understand the role of mGlu4 in regulation of basal 
ganglia function, we evaluated the ability of PHCCC to reduce corticostriatal 
transmission. In agreement with previous results (Pisani et al., 1997), 100 µM L-AP4, a 
group III selective mGlu receptor agonist, reduced evoked excitatory postsynaptic 
potentials (eEPSPs) measured in striatal medium spiny neurons following stimulation in 
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the corpus callosum (42.8 ± 5.8% of baseline; Figure 3.1A).  To determine if PHCCC 
could potentiate the response to L-AP4, a concentration of L-AP4 that resulted in a small 
reduction in the eEPSP amplitude was identified.  500 nM L-AP4 resulted in reduction in 
the eEPSP amplitude that was at the threshold for detection (90.5 ± 6.2% of baseline; 
Figure 3.1B).  Surprisingly, PHCCC did not potentiate the response to L-AP4 at this 
synapse; 30 µM PHCCC, followed by the co-addition of 30 µM PHCCC + 500 nM L-
AP4, resulted in no change in eEPSP amplitude (90.1 ± 7.1% of baseline; Figure 3.1C) 
relative to 500 nM L-AP4 alone. 
 
The lack of effect of PHCCC was surprising and contrasts with the ability of this 
compound to potentiate mGlu4 activity at other synapses (Jones et al., 2008; Marino et al., 
2003; Valenti et al., 2005). In addition, this finding does not align with the ability of the 
structurally distinct mGlu4–selective PAM Lu AF21934 to potentiate mGlu4 agonist 
effects at corticostriatal synapses (Bennouar et al., 2012). Interestingly, both the group II 
mGlu agonist LY379268 (Picconi et al., 2002) and the mGlu2 PAM cyPPTS (Johnson et 
al., 2005) inhibit excitatory transmission at corticostriatal synapses via a presynaptic 
mechanism of action, suggesting that mGlu2 receptors are also expressed on 
corticostriatal terminals. Recent studies including time-resolved FRET and co-expression 
studies have shown that mGlu2 and mGlu4 form heterodimers in vitro (Doumazane et al., 
2011a; Kammermeier, 2012) and we hypothesized that mGlu4-containing heteromers may 
be expressed on corticostriatal terminals and may not display the same response to 
PHCCC as that observed with mGlu4 homomers. 
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To test this hypothesis, an mGlu2/4 cell line was constructed by transfecting rat mGlu4 
into rat mGlu2/HEK cells stably expressing G Protein Inwardly Rectifying Potassium 
(GIRK) channels, which allows assessment of receptor activity using a GIRK-mediated 
thallium flux assay (Niswender et al., 2008a). We established that the resulting mGlu2/4 
cell line expressed similar amounts of both mGlu2 and mGlu4 protein compared to the 
parental cell lines expressing either receptor alone (Figure 3.2). We then assessed the 
physical interaction between mGlu2 and mGlu4 using co-immunoprecipitation techniques. 
mGlu4 antibodies immunoprecipitated mGlu4 protein (~240 kDa in dimeric form) from 
the cell lysate of the mGlu4 and mGlu2/4 cell lines (Figure 3.3B). A band of 
approximately 100 kDa was present in all of the immunoprecipitation (IP) samples and 
obscured specific identification of monomeric receptor protein; this band was present in 
IP samples without any cell lysate (data not shown), suggesting that it resulted from the 
antibody itself. In cells co-expressing mGlu2 and mGlu4, mGlu2 proteins were co-
precipitated along with mGlu4 by mGlu4 antibody-coupled beads (Figure 3.3D; ~100 kDa 
and ~240 kDa for monomeric and dimeric forms, respectively). In contrast, precipitation 
using the protein A/G beads alone did not yield any specific bands. Additionally, 
precipitated mGlu2 was not detected in IPs from the control mGlu2 or mGlu4 cell line. To 
eliminate the possibility that mGlu2 and mGlu4 proteins nonspecifically aggregated after 
the cells were lysed, we mixed the cell lysates from the mGlu2-expressing cell line and 
the mGlu4-expressing cell line and subjected the mixed sample to co-IP. The absence of 
precipitated mGlu2 in this mixed sample indicated that mGlu2/4 complexes were formed 
before, but not during or after, the lysis process. We further confirmed the physical 
interaction between mGlu2 and mGlu4 by swapping the bait and prey in additional co-IP 	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Figure 3.1. The mGlu4 PAM PHCCC fails to potentiate L-AP4-induced decreases in 
evoked EPSPs at corticostriatal synapses. EPSPs were recorded in medium spiny 
neurons following stimulation of the white matter between the cortex and striatum with a 
bipolar electrode.  All compounds were bath applied. Data are normalized to the average 
baseline EPSP amplitude. Insets are sample traces from an individual, representative 
experiment (black – averaged traces from minute prior to L-AP4 application; gray – 
averaged traces from last minute of L-AP4 application). Slices were treated with 100 µM 
L-AP4 (A), 500 nM L-AP4 (B) or 30 µM PHCCC followed by co-application of 30 µM 
PHCCC and 500 nM L-AP4 (C). Solid and dashed lines represent time of compound 
additions. Values represent mean ± SEM (n=5).  
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Figure 3.2. Similar expression levels of mGlu2 and mGlu4 in various cell lines. 15 µg 
of cell lysates from mGlu2, mGlu2/4 and mGlu4 cell lines were prepared as described. 
Receptor expression was analyzed by western blots using anti-mGlu2 (panel A, 1:1000 
dilution) and anti-mGlu4 (panel B; 1:1000 dilution) antibodies. 
 
  
Anti-mGlu2
A
Anti-mGlu4
B
260
100
260
100
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experiments. When mGlu2 was used as the bait, mGlu4 proteins were also co-
immunoprecipitated by mGlu2 antibodies only in the cell line that expressed both 
receptors (Figure 3.3H). These data support the hypothesis that mGlu2 specifically 	  
interacts in some manner with mGlu4 in vitro and can be co-immunoprecipitated with 
antibodies recognizing the native receptor proteins. 
 
After optimizing conditions for co-immunoprecipitation of mGlu2 and mGlu4 in cell lines, 
we tested the hypothesis that these receptors interact in brain tissue.  Both mGlu2 and 
mGlu4 are expressed in dorsal striatum and medial prefrontal cortex of Sprague-	  	  
Dawley rats, as indicated by the immuno-reactive monomeric and dimeric bands in tissue 
lysates (Figure 3.4, input). While both mGlu4 antibodies and a rabbit IgG control 
generated antibody bands at around 100 kDa, mGlu4 antibodies were able to precipitate 
dimeric mGlu4 from the dorsal striatum and medial prefrontal cortex (~240 kDa in 
dimeric form; Figure 3.4A and B). Conversely, immunoprecipitation using rabbit IgG did 
not yield any mGlu4-specific bands. In addition, when detected using mGlu2-specific 
antibodies, we found that mGlu2 proteins were co-immunoprecipitated by mGlu4 
antibodies in both monomeric and dimeric forms (~100 kDa and 240 kDa respectively), 
but not by rabbit IgG (Figure 3.4C and D). Similar results were also obtained in mouse 
dorsal striatum and medial prefrontal cortex (Figure 4E-H). Taken together, these data 
present the first evidence consistent with the existence of mGlu heteromers in vivo and 
suggest that mGlu2/4 heteromers may participate in the regulation of CNS function.  
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mGlu2/4 heteromer differentially regulate the effect of mGlu4 allosteric modulators  
 
To further test the hypothesis that the lack of efficacy of PHCCC at the corticostriatal 
synapse was due to expression of mGlu4-containing heteromers, the pharmacology of 
mGlu2/4 receptors was extensively characterized using the thallium flux assay (Niswender 
et al., 2008a). In these studies, the initial slopes (starting 5 seconds after thallium addition 
and then measured over a 10 second time span) of inward flux of thallium are calculated 
and plotted as agonist-induced concentration-response curves (samples traces of thallium 
flux assays are shown in Figure 3.5A-C and represent the data used to generate the L-
AP4 curves in panel 3.5F). Glutamate, the orthosteric agonist for both mGlu2 and mGlu4, 
exhibited a pEC50 value of 6.22±0.03 in the mGlu2/4 cell line. This potency was similar to 
the pEC50 of glutamate at mGlu2 (6.08±0.03) compared to that of mGlu4 (4.79±0.03) 
(Figure 3.5D, Table 3.1). To further characterize each of the subtypes in the 
heterocomplex, more selective agonists were utilized for mGlu2 (LY379268) or mGlu4 
(L-AP4) (Figure 5E and F). In the mGlu2/4 cell line, the mGlu2 agonist LY379268 elicited 
a full agonist response with a slightly reduced potency comparing to cells expressing 
mGlu2 alone (Figure 3.5E, Table 3.1). Likewise, L-AP4, the mGlu4 selective agonist, 
induced an agonist response with similar potency in cells expressing mGlu2/4 and mGlu4 
alone. Unlike LY379268, L-AP4 was only able to elicit about 70% of the maximum 
response generated by glutamate in mGlu2/4 cells. Additionally, we observed a significant 
decrease in the Hill slope of the curve fits for both LY379268 and L-AP4 in mGlu2/4-co-
expressing cells (Table 3.1), indicating an interaction between the two proteins and 
supporting the hypothesis that the mGlu2/4 complex possesses distinct pharmacological 
properties.  
	   79	  	  
 
We then investigated whether mGlu2 and mGlu4 agonist sites interact with each other in 
mGlu2/4-expressing cells. A serial dilution of L-AP4 was applied either alone or in the 
presence of 0.5 nM or 1 nM LY379268. In the mGlu4 cell line, neither concentration of 
LY379268 produced any effect on L-AP4 responses compared to buffer control (Figure 3. 
6A). When assessed in the mGlu2/4 cell line, LY379268 dose-dependently shifted the L-
AP4 dose response curve to the left (Figure 3.6B), suggesting a potentiating effect by co-
activation of the mGlu2 subunit. In support of an interaction between subunits, 0.1, 10 
and 100 nM L-AP4 dramatically potentiate the responses induced by LY379268 as well 
(Figure 3.6C and D).  
 
After assessing the activity of orthosteric agonists in cells expressing either receptor 
alone or expressing the combination, we moved to an analysis of potential effects on the 
pharmacology of allosteric modulators for mGlu4 and mGlu2 (structures shown in Figure 
3.7). Advantages if focusing our studies on mGlu2 and mGlu4 are that 1) these receptors 
are co-expressed in many brain regions, and 2) there are a number of orthosteric and 
allosteric ligands that differentiate between mGlu2 and mGlu4, allowing us to generate a 
tool set of ligands appropriate for native tissue studies. 10 µM PHCCC induced a 
4.7±0.02 fold leftward shift of the L-AP4 response in cells expressing mGlu4 alone  
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Figure 3.3. mGlu2 and mGlu4 are co-immunoprecipitated from Human Embryonic 
Kidney (HEK) cells. mGlu4 antibodies (A-D) or mGlu2 antibodies (E-H) were used for 
co-immunoprecipitation. Cell lysates from mGlu2/4, mGlu2, and mGlu4 cell lines, together 
with lysates from mGlu2 cells and mGlu4 cells that were mixed after lysis, were subjected 
to co-IP experiments. Cell lysates from mGlu2/4 cells were also precipitated by protein 
A/G beads without antibody as a negative control (A/G control). Precipitated proteins 
from different samples were analyzed by western blots. Cell lysates before co-IP 
experiments were loaded as indication of IP input (left side panels). Molecular sizes of 
mGlu2 or mGlu4 (~100 kDa and ~240 kDa for monomeric and dimeric forms, 
respectively) are indicated with arrows.  
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Figure 3.4. mGlu4 antibodies co-immunoprecipitate mGlu2 protein from rodent 
dorsal striatum and medial prefrontal cortex. Dorsal striatum and medial prefrontal 
cortex extracts from rat (A-D) or mouse (E-H) samples were prepared as described and 
tissue lysates were precipitated using anti-mGlu4 antibody (IP-mGlu4) or rabbit IgG (IgG 
Control). The precipitated proteins were analyzed via western blots and tissue lysates 
before IP experiments were loaded as IP input. Molecular sizes of mGlu2 or mGlu4 (~100 
kDa and ~240 kDa for monomeric and dimeric forms, respectively) are indicated with 
arrows. 
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Figure 3.5. Orthosteric agonist responses are distinct in mGlu2, mGlu4 or mGlu2/4-
expressing cell lines. A-C, sample traces of L-AP4 responses in mGlu2, mGlu4 and 
mGlu2/4 cells with concentrations ranging from 0.1 nM to 10 µM. The initial slopes of the 
raw traces were used to generate concentration response curves shown in F.  D-F, serial 
dilutions of glutamate (D), the group II agonist LY379268 (E) and the group III agonist 
L-AP4 (F) were applied to HEK/GIRK/mGlu2 (■), HEK/GIRK/mGlu4 (▲) and 
HEK/GIRK/mGlu2/4 (●) cell lines and GIRK-mediated thallium flux was measured 
according to protocols described above. Reponses were normalized to the maximal 
response induced by 1 mM glutamate in each individual cell line, and pEC50 values for 
concentration- response curves are shown in Table 1. All values represent mean ± SEM 
(n≥3). 
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Table 3.1. Potencies and efficacies of orthosteric agonists in various cell lines. Data 
represent the Mean±SEM of at least three experiments performed in duplicate.  
ap=0.0034 for mGlu2 versus mGlu2/4 lines; 
bp=0.0161 for mGlu2 versus mGlu2/4 lines; 
cp=0.0049 for mGlu2 versus mGlu2/4 lines; dp<0.0001 for mGlu2 versus mGlu2/4 lines; 
ep<0.0001 for mGlu4 versus mGlu2/4 lines; fp<0.0001 for mGlu4 versus mGlu2/4 lines. 
Unpaired Student’s T test (n≥3, two-tailed). 
 
 
 
 
 
 
 
  
 mGlu2 mGlu4 mGlu2/4 
 pEC50 % Glu Max Hill Slope pEC50 % Glu Max Hill Slope pEC50 % Glu Max Hill Slope 
Glutamate 6.08±0.03 101.0±0.8 1.88±0.08 4.79±0.03 99.1±0.5 1.50±0.03 6.22±0.03a 101.4±0.6 2.01±0.04 
LY379268 8.32±0.02 108.3±0.9 1.73±0.05 >5.0 N/A N/A 8.04±0.10b 101.9±0.9c 1.10±0.10d 
L-AP4  N/A N/A N/A 6.60±0.03 100.9±1.1 1.42±0.03 6.64±0.05 72.8±2.0e 0.91±0.02f 
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 Figure 3.6. Orthosteric agonist of mGlu2 and mGlu4 potentiates effect of each other 
in mGlu2/4-expressing cell line. Buffer control (■), 0.5 nM (●) or 1 nM LY379268 (□) 
were added 140 s before addition of serial dilutions of L-AP4. GIRK channel-mediated 
thallium flux was measured as described in HEK/GIRK/mGlu2, HEK/GIRK/mGlu4 or 
HEK/GIRK/mGlu2/4 cell line and was normalized to the maximal response induced by 1 
mM glutamate. A and B, L-AP4 dose response curves were plotted in the absence or 
presence of LY379268 in mGlu4 or mGlu2/4 cells. C and D, the responses induced by 0, 
0.5 or 1 nM LY379268 were plotted in the absence or presence of L-AP4 in mGlu2 or 
mGlu2/4 cells. Basal responses induced by 0.1, 10 or 100 nM L-AP4 alone were deducted. 
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(Figure 3.8A). In contrast, PHCCC only induced a negligible shift of the L-AP4 response 
in the mGlu2/4 cell line (1.7±0.04 fold, Figure 3.8B). When assessed using glutamate, 10 
µM PHCCC shifted the concentration-response curve to the left by 3.5±0.53 fold in 
mGlu4 cells (Figure 3.8C) but did not potentiate the glutamate response in cells 
expressing both mGlu2 and mGlu4 (1.0±0.04 fold; Figure 3.8D). This loss of efficacy in 
the mGlu2/4 cell line is consistent with a previous report (Kammermeier, 2012) and aligns 
with the lack of significant potentiation of the L-AP4 response we observed with PHCCC 
at corticostriatal synapses (Figure 3.1C). The inability to potentiate mGlu2/4 heteromers 
was not limited to PHCCC alone. 4PAM-2 is a selective and efficacious PAM of mGlu4 
which binds to the same allosteric site as PHCCC (Drolet et al., 2011c). In cells 
expressing mGlu4 alone, 10 µM 4PAM-2 shifted concentration-response curves of L-AP4 
and glutamate by 18.8±2.6 and 15.2±3.1 fold, respectively (Table 3.2). When mGlu2 was 
co-expressed, however, 4-PAM2 only weakly potentiated the L-AP4 response (2.7±0.2 
fold) and was completely ineffective at shifting the glutamate concentration-response 
curve (1.0±0.02 fold; Table 3.2).  
VU0155041 is another mGlu4 PAM derived from a different chemical scaffold compared 
to PHCCC or 4PAM-2. Consistent with our previous report (Niswender et al., 2008b), 
VU0155041 (10 µM) shifted the L-AP4 and glutamate concentration-response curves to 
the left by 3.9±0.3 and 4.0±0.3 fold, respectively, in cells expressing mGlu4 alone 
(Figures 3.8E and G). Interestingly, VU0155041 also induced leftward shifts in the 
agonist concentration response curves in the mGlu2/4 cell line, shifting the L-AP4 
response substantially (9.7±1.0 fold shift), retaining its efficacy in shifting the glutamate 
response (3.5±0.3 fold shift) (Figure 3.7F and H), and, surprisingly, even showing 
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significant potentiation of the LY379268 response (4.2±0.12 fold, Table 3.2). As 
VU0155041 is predicted to bind only to the mGlu4 protein and LY379268 should only 
activate mGlu2, this finding suggests that there is transactivation between the subunits 
within the heteromer. We noted a slight decrease in the maximal response induced by the 
VU0155041/glutamate combination (Figure 3.8H); this was not present when L-AP4 was 
used as the agonist (Figure 3.8) or when mGlu4 was expressed alone (Figure 3.8G). There 
are several possibilities that may explain this phenomenon. For example, there could be 
differences in receptor desensitization induced by the allosteric agonist activity of 
VU0155041 (Niswender et al., 2008b). When the endogenous agonist activity of 
VU0155041 was assessed in the absence of orthosteric agonist, the potency of 
VU0155041 was similar in cells expressing mGlu4 versus those containing mGlu2/4 as 
was the maximal level of potentiation (pEC50 value, mGlu4, -5.38±0.17, and mGlu2/4 cells, 
5.25±0.10 (p=0.5719); maximal response,  mGlu4, 40.5±4.8% of glutamate maximal 
response, and mGlu2/4 cells, 38.9±6.3% of glutamate maximal response  (p=0.8459)), 
suggesting differential desensitization is not the cause of this discrepancy. It is possible 
that the use of glutamate in these experiments may contribute to this change in maximal 
response as glutamate will activate both mGlu2 and mGlu4. The decrease in the maximal 
response occurs at glutamate concentrations that would activate both mGlu2 and mGlu4, 
suggesting that there could be unique responses elicited when both the mGlu2 and mGlu4 
orthosteric sites are occupied. The use of L-AP4, however, would not carry such a caveat, 
and the maximal responses in Figure 3.7F are similar with or without VU0155041. The 
enhanced ability of VU0155041 to potentiate L-AP4 responses was not due to non-  
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Figure 3.7. Structures of allosteric ligands used in these studies. 
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Figure 3.8. The efficacies of PHCCC and VU0155041 are differentially regulated by 
mGlu2/4 co-expression. A-H, 10 µM compound (■) or DMSO (●) were added 140 s 
before addition of serial dilutions of L-AP4 or glutamate. GIRK channel-mediated 
thallium flux was measured as described in HEK/GIRK/mGlu4 (left panels) and 
HEK/GIRK/mGlu2/4 (right panels) cell lines. Reponses were normalized to the maximal 
response induced by 1 mM glutamate in each individual cell line. pEC50 values for dose 
response curves in panels A-D without or with PHCCC were: A, 6.61±0.11 vs. 7.28±0.11 
(p=0.0115); B, 6.63±0.06 vs. 6.85±0.05 (p=0.0557); C, 4.77±0.05 vs. 5.27±0.10 
(p=0.0017); D, 6.11±0.05 vs. 6.09±0.06 (p=0.8383). pEC50 values for dose response 
curves in panel E-H without or with VU0155041 were: E, 6.61±0.11 vs. 7.21±0.08 
(p=0.0113); F, 6.63±0.06 vs. 7.61±0.07 (p=0.0004); G, 4.77±0.05 vs. 5.36±0.04 
(p<0.0001); H, 6.11±0.05 vs. 6.64±0.02 (p<0.0001). All values represent mean ± SEM 
(n≥3).  
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Table 3.2. The ability of mGlu4 PAMs to left-shift agonist concentration-response 
curves is distinct for different groups of PAMs. Data represent the Mean SEM of at 
least three experiments performed in duplicate.  ap=0.0009 for mGlu4 versus mGlu2/4 
lines; bp<0.0001 for mGlu4 versus mGlu2/4 lines; cp=0.0003 for mGlu4 versus mGlu2/4 
lines; dp=0.0034 for mGlu4 versus mGlu2/4 lines; ep<0.0001 for mGlu2 versus mGlu2/4 
lines; fp=0.0054 for mGlu4 versus mGlu2/4 lines; gp=0.0175 for mGlu4 versus mGlu2/4 
lines; hp<0.0001 for mGlu2 versus mGlu2/4 lines; ip=0.0021 for mGlu4 versus mGlu2/4 
lines. Unpaired student’s t-test (n≥3, two-tailed). Note the ability of VU0155041 to shift 
responses of the mGlu2 agonist, LY379268. 
 
 
 
 
  
 mGlu2 mGlu4 mGlu2/4 
 Glutamate LY379268 Glutamate L-AP4 Glutamate LY379268 L-AP4 
10 µM PHCCC 0.9±0.03 1.0±0.04 3.5±0.53 4.7±0.02 1.0±0.04a 0.8±0.07 1.7±0.04b 
10 µM 4PAM-2 0.9±0.03 0.9±0.05 15.2±3.10 18.8±2.58 1.0±0.02c 0.9±0.07 2.7±0.21d 
10 µM VU0155041 0.9±0.02 0.9±0.02 4.0±0.26 3.9±0.29 3.5±0.30 4.1±0.12e 9.7±1.00f 
10 µM  Lu AF21934 1.0±0.03 1.0±0.02 3.4±0.14 3.9±0.08 2.7±0.17g  1.7±0.10h 8.2±0.96i 
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selective activity of VU0155041 on mGlu2 receptors (Table 3.2, (Niswender et al., 
2008b)). These results reveal that VU0155041 can be used as a chemical probe to 
potentiate responses to activation of mGlu2/4 heterodimers.  
The marked distinction between VU0155041 and PHCCC led us to speculate that 
the divergence in effect between the two PAMs may arise from their different chemical 
structures or binding sites; PHCCC and 4-PAM2 have been reported to bind to the same 
site on mGlu4 while VU0155041 appears to bind to a distinct site on the mGlu4 protein 
((Drolet et al., 2011c), assessed using a racemic mixture of VU0155041 regioisomers). 
Consistent with this hypothesis, the VU0155041-related compound, Lu AF21934, also 
exhibited an enhanced ability to potentiate L-AP4 responses (3.9±0.1 fold for mGlu4 cells 
alone and 8.2±1.0 fold for mGlu2/4 cells) and retained the ability to potentiate glutamate  
responses (3.4±0.1 fold, mGlu4 cells; 2.7±0.2 fold, mGlu2/4 cells, Table 3.2) in cells co-
expressing both receptors. 
 
To gain further insight into the mechanism of the pharmacological changes, the ability of 
increasing amounts of compound to induce progressive leftward shifts in agonist 
concentration-response curves was measured using each individual mGlu4 PAM and the 
operational model of allosterism was applied to compare the affinity (log KB) and 
cooperativity (log αβ-a combined parameter that represents the effects of a modulator on 
affinity (α) as well as effects on efficacy (β)) of  PAMs in cells expressing mGlu4 alone 
vs. mGlu2/4. As shown in Table 3.3, the estimated affinity of PHCCC was similar in 
mGlu2/4 cells compared to cells expressing mGlu4 alone. However, the positive 
cooperativity of PHCCC decreased significantly, from 0.57 ± 0.03 in the mGlu4 cell line 
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to 0.12 ± 0.02 in mGlu2/4 cell line (p=0.0017). Similar to PHCCC, 4PAM-2 also 
demonstrated a significant decrease in positive cooperativity in mGlu2/4 cells (log αβ: 
1.29±0.04 in mGlu4 vs. 0.82±0.02 in mGlu2/4 cells, p=0.0006); again, the affinity of the 
compound was not significantly different in the cell line expressing both receptors (Table 
3.3). In contrast, VU0155041 and Lu AF21934 exhibited significant changes in affinity 
(Log KB -5.27±0.01 vs. -4.78±0.13 for VU0155041, p=0.0188 and -5.88±0.04 vs. -
5.26±0.09 for Lu AF21934, p=0.0042) as well as increases in positive cooperativity (log 
αβ 0.95 ± 0.05 vs. 1.83 ± 0.27 for VU0155041, p=0.0334 and 0.66 ± 0.03 versus 1.7 ± 
0.11 for Lu AF21934, p=0.0008) in mGlu2/4 expressing cells compared to cells 
expressing mGlu4 alone. These data suggest the altered pharmacology of mGlu4 PAMs is 
due to differential changes in their positive cooperativity. 
 
The lack of efficacy of PHCCC and 4PAM-2 suggests that the mGlu2/4 cell line in which 
we performed our studies contains few or no mGlu4 homomers, indicating that mGlu2/4 
interactions may be dominant and actually preferred. To further probe the interactions 
between the receptors, we transiently transfected either increasing amounts of mGlu2 
alone, increasing amounts of mGlu2 in the presence of a constant amount of mGlu4, or 
increasing amounts of mGlu2 in the presence of another group III mGlu, mGlu7. mGlu7 
was chosen as Kammermeir  previously reported that mGlu2 and mGlu7 do not appear to 
interact in the same fashion as mGlu2 and mGlu4, suggesting that there is some specificity 
to the interaction (Kammermeier, 2012). In these studies, we observed gradual increases 
in the maximal LY379268 response when mGlu2 was expressed alone in increasing 
amounts (data not shown); at the concentrations used here, we saw no significant 
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differences in the potency (Figure 3.9A) or Hill slope (Figure 3.9B) of the LY379268 
response when mGlu2 was assessed in the absence of other mGlus. In the presence of 
mGlu7, responses appeared similar to those in which mGlu2 alone was expressed, with no 
differences in LY379268 potency or Hill slope (Figure 3.9A and B). In the presence of 
mGlu4, however, the potency of LY379268 was progressively shifted to the left when 
mGlu2 levels were increased; additionally, the Hill slope of the curve fit also 
progressively increased, indicating alterations in cooperativity between the subunits. 
These differences suggest that the mGlu2/4 combination appears to be distinct from that of 
mGlu2/7, indicating some specificity in this interaction and confirming previous work by 
Kammermeier. 
 
 To further demonstrate that the altered pharmacology of mGlu4 PAMs was due to 
mGlu2/4 interaction, we tested the activity of mGlu4 PAMs after transient transfection of 
increasing amounts of mGlu2 in the presence of a constant amount of mGlu4. In these 
experiments, a 30 µM concentration of each PAM was used. In cells transfected with just 
mGlu4, 30 µM of PHCCC induced 7.2±1.5 and 8.5±0.3 fold leftward shifts of the 
glutamate or L-AP4 concentration-response curves, respectively. However, in cells co-
transfected with 0.1, 0.2 and 0.5 µg mGlu2 DNA, the shift of the L-AP4 response 
progressively decreased to 5.8±1.2, 3.5±0.6 and 3.4±0.2 fold, and in cells transfected 
with equal amounts of mGlu2 and mGlu4, the shift was only 1.9±0.5 fold (Figure 3.9C 
and Table 3.4). In addition, the shift of the glutamate response, even with only 0.1 µg of 
mGlu2 DNA present (10% of the amount of mGlu4) drastically decreased to only 1.3±0.1 
fold (Figure 3.8D), suggesting a quite dramatic and dominant effect induced by the 
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presence of mGlu2. As with the responses observed with PHCCC, 4PAM-2 demonstrated 
similar efficacy changes in transiently transfected cells, which is consistent with our 
findings in the stable cell lines and the observation that these two PAMs bind to the same 
allosteric pocket. Interestingly, the potentiation induced by VU0155041 and Lu AF21934 
remained similar as the amount of mGlu2 increased, further supporting the observation 
that distinct classes of mGlu4 PAMs are differentially regulated by mGlu2/4 interactions. It 
should be noted that, in these experiments, the similarity in potencies and Hill slopes of 
LY379268 in mGlu2/4-expressing cells when the mGlu2:4 ratio is 1:1, compared to cells 
expressing mGlu2 alone, suggest that mGlu2 homomers may exist along with mGlu2/4 
heteromers in these experiments. In contrast, our data also suggest that mGlu2/4 
heteromers are the dominant entity for mGlu4 in these experiments. This interpretation is 
supported by the lack of potentiation induced by PHCCC and 4PAM-2 when glutamate is 
used as the agonist and the ratio of mGlu2 to mGlu4 is 1:10, suggesting that co-expression 
of even small amounts of mGlu2 dramatically regulates activity of mGlu4. 
 
Co-addition of mGlu2 PAM and mGlu4 PAM does not result in further potentiation  
We were also intrigued to investigate the cooperatvity of mGlu2 PAM and mGlu4 PAM 
and examined if co-addition of these compounds led to further potentiation in mGlu2/4 
cells compared to the effect induced by single PAM.  1 µM BINA, an mGlu2 PAM, was 
applied either alone or in combination with mGlu4 PAM VU0155041 (Figure 3.10A).  1 
µM BINA, when added alone, induced allosteric agonist activity as can be seen by the 
elevated baseline of the dose response curve, and produced a 2.9±0.8 fold shift of the 
glutamate response. Consistent with previous data, 10 µM VU0155041 was able to shift  
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 Log KB  Log αβ 
 mGlu4 cells mGlu2/4 cells mGlu4 cells mGlu2/4 cells 
PHCCC −5.46 ± 0.23 −5.47 ± 0.09 0.94 ± 0.06 0.51 ± 0.01a 
4PAM-2 −6.32 ± 0.04 −6.44 ±0.06 1.29 ± 0.04 0.82 ± 0.02b 
VU0155041 −5.27 ± 0.01  −4.78 ± 0.13c 0.95 ± 0.05 1.83 ± 0.27d 
Lu AF21934 −5.88 ± 0.04 −5.26 ± 0.09e 0.66 ± 0.03 1.70 ± 0.11f 
 
Table 3.3. Analysis of mGlu4 PAMs using the operational model of allosterism 
reveals differential alterations in affinity or cooperativity for distinct groups of 
PAMs. Data were generated by progressive fold shift experiments using increasing 
concentrations of four mGlu4 PAMs (ranging from 0 to 30 µM) prior to application of a 
full concentration-response range of L-AP4 (ranging from 0.1 nM to 10 µM). The logKA 
of L-AP4 for mGlu4 was set to -6.759 according to literature values (Monastyrskaia et al., 
1999).  For PHCCC and 4PAM-2, logτB was set to -100 due to the lack of allosteric 
agonist activity but was allowed to float for compounds exhibiting allosteric agonism 
(VU0155041, Lu AF29134). Data represent the Mean±SEM of at least three experiments 
performed in duplicate.  ap=0.0017 between mGlu4 cells and mGlu2/4 cells; bp= 0.0006 
between mGlu4 cells and mGlu2/4 cells; cp=0.0188 between mGlu4 cells and mGlu2/4 cells; 
dp=0.0334 between mGlu4 cells and mGlu2/4 cells; ep=0.0042 between mGlu4 cells and 
mGlu2/4 cells; fp=0.0008 between mGlu4 cells and mGlu2/4 cells. Unpaired student’s t-test 
(n≥3, two-tailed). 
  
	   98	  	  
 
  Glutamate CRC L-AP4 CRC 
DNA  
(mGlu4+mGlu2, µg) 1+0 1+0.1 1+0.2 1+0.5 1+1 1+0 1+0.1 1+0.2 1+0.5 1+1 
PHCCC 7.2±1.5 1.3±0.1∗∗∗ 1.7±0.1∗∗∗ 1.3±0.01∗∗∗ 1.2±0.1∗∗∗ 8.5±0.3 5.8±1.2∗ 3.5±0.6∗∗ 3.4±0.2∗∗∗ 1.9±0.5∗∗∗ 
4-PAM2 10.0±1.1 1.5±0.1∗∗∗ 1.6±0.2∗∗∗ 1.3±0.04∗∗∗ 1.3±0.1∗∗∗ 14.7±2.6 9.6±3.2 5.2±0.2∗ 4.8±1.2∗ 2.4±0.5∗∗ 
VU0155041 4.4±0.8 4.8±0.4 5.3±0.9 4.9±0.1 4.1±0.3 6.3±2.1 8.8±3.8 3.7±0.7 7.6±0.5 3.9±0.6 
Lu AF21934 3.7±0.9 4.6±0.5 5.3±0.7 4.4±0.4 3.9±0.1 2.6±0.4 3.6±1.2 3.5±0.8 4.2±0.4 2.1±1.0 
 
Table 3.4. Differential leftward fold shifts of glutamate or L-AP4 concentration-
response curves are induced by different PAMs after transient expression of 
increasing amounts of mGlu2 (0, 0.1, 0.2, 0.5 or 1 µg) with a constant amount (1 µg) 
of mGlu4.  Data represent the Mean ± SEM of three independent experiments 
performed in duplicate. Data were analyzed using one way ANOVA and Dunnett’s 
Multiple Comparison Test comparing to cells transfected with mGlu4 alone: *p<0.05, 
**p<0.01, ***p<0.001. 
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Figure 3.9. Co-expression of varying amounts of mGlu2 and mGlu4 regulates 
responses to both orthosteric and allosteric ligands. HEK/GIRK cells were transfected 
with 0, 0.1, 0.2, 0.5 or 1 µg mGlu2 DNA in the absence or presence of co-transfection of 
1 µg of vector control, 1 µg mGlu7, or 1 µg mGlu4. A and B. Potencies and Hill slope of 
the LY379268 response were determined; responses were unaffected by empty vector or 
mGlu7 but dramatically altered in the presence of mGlu4. C and D. The fold shifts 
induced by 30 µM of PHCCC, 4PAM-2, VU0155041 or Lu AF21934 are summarized for 
L-AP4 (C) and glutamate (D) using bar graphs. Values represent mean ± SEM (n=3). 
Statistics were performed using 1way ANOVA, Bonferroni’s Multiple Comparison Test 
was used for A and B and Dunnett’s Multiple Comparison Test was used for C and D. * 
denotes p < 0.05; ** denotes p<0.01 and *** denotes p<0.001. 
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 Figure 3.10. Co-addtion of mGlu2 PAM and mGlu4 PAM does not result in further 
potentiation. A-C, DMSO control (■), 1 µM BINA (▼), 10 µM mGlu4 PAM (●, 
VU0155041, PHCCC or 4PAM-2) or BINA plus mGlu4 PAM (□) were added 140 s 
before addition of serial dilutions of glutamate. GIRK channel-mediated thallium flux 
was measured as described in HEK/GIRK/mGlu2/4 cell line and was normalized to the 
maximal response induced by 1 mM glutamate. pEC50 values for dose response curves of 
DMSO and 1 µM BINA were 6.10±0.05 and 6.48±0.16, respectively.  pEC50 values for 
dose response curves of mGlu4 PAM and BINA plus mGlu4 PAM in panels A-C were: A, 
6.64±0.02 vs. 6.79±0.05; B, 6.09±0.06 vs. 6.44±0.15; C, 6.12±0.05 vs. 6.60±0.14. All 
values represent mean ± SEM (n≥3).  
 
 
m G lu 2 /4
-1 0 -9 -8 -7 -6 -5 -4 -3 -2
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
D M S O
1  u M  B IN A
1 0  u M  V U 0 1 5 5 0 4 1
B IN A + V U 0 1 5 5 0 4 1
L o g  [G lu ta m a te ], M
P
e
rc
e
n
t 
M
a
x
G
lu
ta
m
a
te
 R
e
s
p
o
n
s
e
m G lu 2 /4
-1 0 -9 -8 -7 -6 -5 -4 -3 -2
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
D M S O
1  u M  B IN A
1 0  u M  P H C C C
B IN A + P H C C C
L o g  [G lu ta m a te ], M
P
e
rc
e
n
t 
M
a
x
G
lu
ta
m
a
te
 R
e
s
p
o
n
s
e
A 
B C m G lu 2 /4
-1 0 -9 -8 -7 -6 -5 -4 -3 -2
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
D M S O
1  u M  B IN A
1 0  u M  4 P A M -2
B IN A + 4 P A M -2
L o g  G lu ta m a te , [M ]
P
e
rc
e
n
t 
M
a
x
G
lu
ta
m
a
te
 R
e
s
p
o
n
s
e
	   101	  	  
glutamate dose response curve to the left by 3.5±0.3 fold. When added together, the 
induced fold shift was 5.0±0.3 fold, considerably lower than the expected value if the 
mGlu2 PAM and mGlu4 PAM exhibited an additive or cooperative effect. As shown in 
Table 3.2, PHCCC or 4PAM-2 was not able to shift glutamate responses when added 
alone in mGlu2/4 cells (Figure 3.10 B and C). The effect of these two mGlu4 PAMs were 
then assessed to determine if their efficacies could be modified in the presence of BINA. 
Co-addition of BINA resulted in a fold shift value that is not significantly higher than 
BINA alone (2.61±0.81 for PHCCC and 3.37±0.96 for 4PAM-2), suggesting no 
cooperative effect between mGlu2 and mGlu4 PAM sites. 
 
Allosteric modulators of mGlu2 are also differentially regulated upon formation of 
mGlu2/4 heteromer  
 
We also sought to investigate the influence of mGlu2/4 interaction on mGlu2 allosteric 
modulators. CBiPES and LY487379 are two PAMs from the pyridylmethylsulfonamide 
series that selectively potentiate mGlu2 (Johnson et al., 2003; Johnson et al., 2005), 
whereas BINA was identified from a different chemical scaffold (Galici et al., 2006). We 
took advantage of these structurally distinct compounds and compared their efficacy in 
cells expressing mGlu2 alone versus cells co-expressing mGlu2 and mGlu4. As shown in 
Table 3.5, none of the mGlu2 PAMs potentiated responses to the mGlu4 agonist L-AP4 in 
either mGlu4 or mGlu2/4-expressing cells. 1 µM BINA induced a 6.7 ±0.6 fold leftward 
shift of the glutamate concentration-response curve in mGlu2 cells (Figure 3.11A). 
However, this number significantly decreased, to 3.0 ± 0.5 fold, in cells expressing both 
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mGlu2 and mGlu4 (Figure 3.11B). Likewise, the fold shift of the LY379628 response 
significantly decreased from 4.0 ±1.1 fold in mGlu2 cells to 1.7 ± 0.2 fold in mGlu2/4 cells 
(Figure 3.11C, D). In contrast, the ability of the mGlu2 PAMs LY487379 and CBiPES to 
potentiate either glutamate or LY379268 responses was not significantly altered (Figure 
3.11E-L), suggesting that distinct mGlu2 PAMs also possess different pharmacological 
profiles when mGlu2 is expressed alone relative to when mGlu2 and mGlu4 are co-
expressed.   
 
In contrast to what was observed with VU0155041/Lu AF21934 and their ability to 
potentiate LY379268 responses, we did not see potentiation of L-AP4 responses with any 
of the mGlu2 PAMs.  Each of the mGlu2 PAMs used here exhibits similar potentiation of 
mGlu2 responses compared to the responses of VU0155041 and Lu AF21934 at mGlu4 
(3-6 fold), suggesting that our assay system should be sensitive enough to detect 
potentiation of an mGlu4 agonist response. However, in contrast to responses to mGlu4 
agonists, we would note that there is possibly some masking of potentiation due to 
expression of mGlu2 homodimers in our cells. Each of the mGlu2 PAMs used here shows 
some degree of allosteric agonist activity, which may complicate measurement of the 
signal when L-AP4 is used as the orthosteric agonist. In contrast to mGlu4, where we 
hypothesize most of the receptors are in heteromeric form, this may result in a loss of 
sensitivity. Additionally, these compounds could be engaging distinct sites on each 
receptor that translate to distinct abilities to induce potentiation. Our data actually are 
most consistent with the hypothesis that the two halves of the heteromer may not function 
symmetrically or may differentially interact with signaling components, such as G-
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proteins. If correct, this might suggest that one half of the dimer may be more sensitive to 
potentiation (or antagonism). While this remains to be determined experimentally for 
mGlu2/4 heteromers and will require an assay system in which absolutely no mGlu2 
homomers are present, it could eventually contribute to signaling differences induced 
downstream of heteromic receptors when specific modulators are used.   
 
Unlike PHCCC, all mGlu2 PAMs evaluated had some activity at both mGlu2 and mGlu2/4, 
suggesting that either these cells express some level of homomeric mGlu2 or that the 
effect on potentiation is not as dramatic as that observed with the mGlu4 PAMs examined 
thusfar; regardless, the ability of these PAMs to each retain some degree of potentiation 
indicates that these compounds may not be useful as selective probes for differentiating 
homomeric versus heteromeric receptors in native systems. 
 
In addition to the evaluation of the efficacy of mGlu2 PAMs, we also assessed the 
efficacy of MNI-137, a selective group II mGlu NAM, on mGlu2 versus mGlu2/4 
responses (Figure  3.12). For these studies, we chose to use the group II agonist DCG-IV, 
as LY379268 will weakly activate mGlu4 at the higher concentrations needed to assess 
whether any potential interaction was competitive or noncompetitive in nature. In cells 
expressing mGlu2 alone, increasing concentrations of MNI-137 non-competitively 
antagonized activation of mGlu2 by DCG-IV, completely abolishing the response (Figure 
3.10A). Consistent with its previously reported selectivity profile (Hemstapat et al., 2007), 
MNI-137 showed no significant effect in blocking L-AP4 responses in cells expressing 
mGlu4 alone (Figure 3.10B). In mGlu2/4 cells, MNI-137 was still able to  
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Table 3.5. The efficacy of mGlu2 PAMs to left-shift agonist concentration-response 
curves differs between classes of PAMs. Data represent the Mean ± SEM of three 
independent experiments performed in duplicate. ap=0.0003 for mGlu2 versus mGlu2/4 
lines; bp=0.0466 for mGlu2 versus mGlu2/4 lines. Unpaired student’s t-test (n≥3, two-
tailed). 
  
 mGlu2 mGlu4 mGlu2/4 
 Glutamate LY379268 Glutamate L-AP4 Glutamate LY379268 L-AP4 
1 µM BINA 6.7±0.6 4.0±1.0 0.9±0.03 0.9±0.1 3.0±0.5a 1.7±0.2b 1.2±0.2 
1 µM LY487379 3.2±0.2 2.1±0.3 0.9±0.02 1.0±0.1 2.7±0.3 2.1±0.3 1.0±0.05 
1 µM CBiPES 6.2±0.3 3.0±0.02 0.8±0.1 0.9±0.04 5.1±0.3 2.8±0.7 0.9±0.2 
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Figure 3.11. The efficacies of mGlu2 PAMs are also differentially regulated by 
mGlu2/4 co-expression. 1 µM compound (■) or DMSO (●) were added 140 s before 
addition of serial dilutions of glutamate or LY379268. GIRK channel-mediated thallium 
flux was measured as described in HEK/GIRK/mGlu2 (left panels) and 
HEK/GIRK/mGlu2/4 (right panels) cell lines. Reponses were normalized to the maximal 
response induced by 1 mM glutamate in each individual cell line. pEC50 values for 
concentration response curves in panels A-D without or with BINA were: A, 6.01±0.03 
vs. 6.81±0.05 (p<0.0001); B, 6.18±0.04 vs. 6.59±0.10 (p<0.0001); C, 8.25±0.02 vs. 
8.79±0.10 (p<0.0001); D, 8.02±0.09 vs. 8.22±0.13 (p=0.0058). pEC50 values for dose 
response curves in panel E-H without or with LY487379 were: E, 5.96±0.01 vs. 
6.47±0.03 (p<0.0001); F, 6.27±0.01 vs. 6.69±0.05 (p<0.0001); G, 8.20±0.02 vs. 
8.52±0.05 (p=0.0003); H, 8.15±0.03 vs. 8.45±0.05 (p=0.0009). pEC50 values for dose 
response curves in panel I-L without or with CBiPES were: I, 5.97±0.01 vs. 6.76±0.02 
(p<0.0001); J, 6.25±0.01 vs. 6.96±0.03 (p<0.0001); K, 8.20±0.01 vs. 8.68±0.01 
(p<0.0001); L, 8.13±0.05 vs. 8.54±0.08 (p=0.0132). All values represent mean ± SEM 
(n≥3) and statistics were performed using unpaired t test. 
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Figure 3.12. MNI-137 exhibits reduced efficacy when mGlu4 and mGlu2 are co-
expressed and non-competitively antagonizes mGlu4-mediated responses in mGlu2/4-
expressing cells. A and B, the effect of MNI-137 on DCG-IV responses were tested in 
the mGlu2 or mGlu2/4 cell line. C and D, the effect of MNI-137 on L-AP4 responses was 
tested in mGlu4 or mGlu2/4 cell line. DMSO (●) or 100 nM, 300 nM, 1 µM or 10 µM 
MNI-137 were added 140 s before addition of serial dilutions of LY379268 or L-AP4. 
GIRK channel-mediated thallium flux was measured as described and responses were 
normalized to the maximal response induced by 1 mM glutamate in each individual cell 
line. All values represent mean ± SEM (n=3).  
 
A B
C D L-AP4 mGlu2/4
Log agonist, [M]
P
er
ce
nt
 M
ax
G
lu
ta
m
at
e 
R
es
po
ns
e
-11 -10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
120
L-AP4 mGlu4
Log agonist, [M]
P
er
ce
nt
 M
ax
G
lu
ta
m
at
e 
R
es
po
ns
e
-11 -10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
120
DCG-IV mGlu2
-10 -9 -8 -7 -6 -5 -4 -3 -2
0
30
60
90
120
150 DMSO
100 nM MNI-137
300 nM
1 uM
10 uM
Log agonist, [M]
P
er
ce
nt
 M
ax
G
lu
ta
m
at
e 
R
es
po
ns
e
DCG-IV mGlu2/4
-10 -9 -8 -7 -6 -5 -4 -3 -2
0
30
60
90
120
150
Log agonist, [M]
P
er
ce
nt
 M
ax
G
lu
ta
m
at
e 
R
es
po
ns
e
	   108	  	  
antagonize DCG-IV responses in a non-competitive manner (Figure 3.12C). Analysis 
using the operational model of allosterism suggested that the affinity of MNI-137 was 
slightly higher in mGlu2/4 cells. In addition, MNI-137 demonstrates increased 
cooperativity for affinity modulation but decreased cooperativity for efficacy modulation 
at mGlu2/4 (Table 3.6), evidenced by an inability to completely abolish the response to 
DCG-IV. Surprisingly, MNI-137 was also able to noncompetitively block activation of 
the mGlu4 subunit induced by stimulation with L-AP4, further supporting a structural and 
functional inter-subunit interaction within the mGlu2/4 complex and suggesting that MNI-
137 binding to mGlu2 can negatively modulate the function of mGlu4. Since MNI-137 
does not block responses to L-AP4 unless mGlu2 is co-expressed with mGlu4, this NAM 
provides an excellent tool to evaluate responses to L-AP4 that may be mediated by 
mGlu2/4 in native systems.  
 
mGlu2 and 4 allosteric modulators exhibit unique pharmacological effect at the 
corticostriatal synapse  
 
The unique pharmacology of VU0155041 and MNI-137 on mGlu2/4-elicited responses 
suggests that these compounds provide a pair of tool compounds that can be utilized to 
provide evidence for the existence of mGlu2/4 heteromers in native systems. Therefore, 
the effect of these two compounds were tested at the corticostriatal synapses by Meredith 
Noetzel and Kari Johnson in our laboratory. Treatment of slices with 10 µM VU0155041, 
followed by the co-addition of 10 µM VU0155041 and 500 nM L-AP4, resulted in a 
robust decrease in the eEPSP amplitude (51.3 ± 4.0% of baseline; Figure 3.13) relative to 
that observed with 500 nM L-AP4 alone (90.5 ± 6.2 % of baseline; Figure 3.1). These 
results, together with the lack of efficacy of PHCCC at the corticostriatal synapse, 
suggest that, in a native system, the potentiation of the L-AP4 responses by mGlu4 PAMs 
mimics the differential responses observed in cells co-expressing mGlu2 and mGlu4.  
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Parameters mGlu2 mGlu2/4 
Log KB −6.82±0.04 −7.18±0.03a 
Log α −0.47±0.05 −0.74±0.05b 
Log β −100 −0.69±0.04 
 
Table 3.6. MNI-137 exhibits enhanced affinity but decreased efficacy in modulating 
DCV-IV responses in mGlu2/4 cells compared to cells expressing mGlu2 alone. Data 
were analyzed using the operational model of allosterism as described in the Materials 
and Methods. The logKA of DCG-IV for mGlu2 was set to -6.959 according to literature 
values; logτB was set to -100. Data represent the Mean ± SEM of three independent 
experiments performed in duplicate. ap=0.0028 between mGlu2 cells and mGlu2/4 cells; 
bp=0.0206 between mGlu2 cells and mGlu2/4 cells. Unpaired student’s t-test (n≥3, two-
tailed). 
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Furthermore, these results suggest that homomeric mGlu4 receptors, which would be 
predicted to respond to PHCCC, are expressed at extremely low abundance, if at all, in 
these synaptic terminals.  
  
If mGlu2/4 heteromeric receptors play a dominant role in regulating transmission at 
corticostriatal synapses, we would also predict that the mGlu2 and mGlu2/4 NAM MNI-
137 would inhibit the effect of L-AP4 at this synapse.  Treatment of slices with L-AP4 
(100 µM) robustly inhibited the amplitude of electrically evoked EPSPs in striatal MSNs 
(62.3 ± 4.8% of baseline, Figure 3.14A). Bath application of MNI-137 (10 µM) for 10 
min produced a small increase in EPSP amplitude (112.7 ± 3.5% of baseline, Figure 
3.14B). Following pretreatment with MNI-137, 10 min bath application of L-AP4, in 
combination with MNI-137, returned EPSP amplitudes to baseline values (100.1 ± 3.4%  
of baseline, Figure 3.14B) and produced significantly less inhibition of EPSP amplitude 
compared with L-AP4 alone. The average inhibition of EPSP amplitude for L-AP4 alone 
was 37.1 ± 5.8%, whereas the L-AP4-induced inhibition of EPSP amplitude following 
MNI-137 treatment was only 12.5 ± 2.7% (P<0.05, unpaired t test, Figure 3.14C). These 
results indicate that an mGlu2 NAM can regulate the responses of an mGlu4 agonist at 
corticostriatal synapses, providing additional evidence for mGlu2/4 heteromer expression 
in vivo. 
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Figure 3.13. In contrast to PHCCC, VU0155041 potentiates the L-AP4-induced 
decrease in evoked EPSPs at the corticostriatal synapse. EPSPs were recorded in 
medium spiny neurons following stimulation of the white matter between the cortex and 
striatum with a bipolar electrode.  All compounds were bath applied. Data are normalized 
to the average baseline EPSP amplitude. Insets are sample traces from an individual 
experiment (black – averaged traces from minute prior to L-AP4 application; gray – 
averaged traces from last minute of L-AP4 application). Slices were treated with 10 µM 
VU0155041 followed by co-application of 10 µM VU0155041 and 500 nM L-AP4. Two 
slices exhibited responses when VU0155041 was applied alone. Solid and dashed lines 
represent time of compound additions (A). Bar graphs summarizing the normalized peak 
EPSP response measured during the last two minutes of compound addition (B). Values 
represent mean ± SEM (n=5). * denotes p < 0.05 when compared to 500 nM L-AP4 using 
Dunnett’s Multiple Comparison Test.  
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Figure 3.14. MNI-137 blocks L-AP4-induced inhibition of corticostriatal 
transmission. EPSPs were recorded in medium spiny neurons following stimulation of 
the white matter between the cortex and striatum with a bipolar electrode. Data are 
normalized to the average baseline EPSP amplitude. Insets represent sample traces from a 
representative experiment (black – averaged traces from minute prior to L-AP4 
application; gray – averaged traces from last minute of L-AP4 application). Slices were 
treated with 100 µM L-AP4 alone (A) or following a 10 minute pretreatment with 10 µM 
MNI-137 (B). (C) Bar graph representation of the inhibition of corticostriatal 
transmission by L-AP4 in the absence (control) and presence of MNI-137. The difference 
between EPSP amplitudes during the minute prior to L-AP4 application and the last 
minute of L-AP4 application were calculated for each cell, and the average difference for 
each treatment group is shown in the bar graph. Data represent mean ± SEM (n=5-7). * 
denotes P < 0.05, unpaired t test. 
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Discussion 
 
As recombinant cell lines are used to identify and characterize allosteric reagents, it is 
important to recognize potential discrepancies between in vitro and in vivo properties of 
these novel compounds.  For example, MMPIP, an allosteric antagonist of mGlu7, 
inhibits mGlu7 activity in recombinant cell lines (Mitsukawa et al., 2005; Niswender et al., 
2010; Suzuki et al., 2007) ; however, when applied to brain slices, it fails to inhibit 
mGlu7-mediated L-AP4 responses at SC-CA1 synapses (Niswender et al., 2010). We 
show here that PHCCC fails to potentiate mGlu4 at corticostriatal synapses, despite its 
well-established efficacy in vitro and at other synapses. These data suggest that the 
activity of allosteric compounds may be context-specific and could be dramatically 
altered by the in vivo environment, such as differential expression of signaling pathway 
components or variations in receptor assembly.  
 
By performing co-IP experiments in dorsal striatum and medial prefrontal cortex from 
both rat and mouse, our data demonstrate mGlu2/4 interaction in native tissue. The 
detection of mGlu2/4 heteromers in dorsal striatum is consistent with electrophysiology 
data that both mGlu2 and mGlu4 act presynaptically to reduce excitatory transmission at 
corticostriatal synapses (Bennouar et al., 2012; Johnson et al., 2005), although mGlu2 and 
mGlu4 may colocalize on other axon terminals in the striatum as well. Similarly, our 
medial prefrontal cortex samples contain many axon terminals where mGlu2 and mGlu4 
might colocalize. While we cannot conclude the precise localization of mGlu2/4 
heteromers in this region, physiological evidence suggests that presynaptic expression of 
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mGlu2 and mGlu4 at thalamocortical synapses (Benneyworth et al., 2007; Marek et al., 
2000; Zhang and Marek, 2007) is also a potential source of the mGlu2/4 heterocomplexes.   
 
We have observed altered efficacies of mGlu4 PAMs in cells co-expressing mGlu2 and 
mGlu4 (Figure 3.8 and Table 3.2). These data are consistent with Kammermeier’s finding 
in in vitro cultured neurons co-injected with mGlu2 and mGlu4 cDNA (Kammermeier, 
2012). We have also shown that effects of mGlu2 allosteric modulators can also be 
significantly altered. Modeling of mGlu4 PAM interactions using the operational model 
of allosterism suggests that binding to two distinct allosteric pockets results in differential 
pharmacological profile changes with regards to affinity and cooperativity. This suggests 
that these allosteric binding pockets may encounter differential conformation changes 
upon heterointeraction of the two receptor subunits, although more detailed structural 
studies are needed.  
 
In our experiments, mGlu2 and mGlu4 were co-transfected without being forced to form 
an interaction. Advantages of this approach are that it avoids tagging of the receptors, 
which may affect pharmacology, and that it more closely mimics the receptor assembly in 
an in vivo environment where mGlu homomers and heteromers may co-exist. At the 
receptor levels expressed in our stable cell lines, the pharmacology of orthosteric agonists, 
such as LY379268 and L-AP4, was not dramatically altered in the mGlu2/4 line (Figure 
3.5). However, although both agonists elicited a response alone, the Hill slopes of the 
concentration-response curves were significantly decreased compared to cells expressing 
a single mGlu subtype, suggesting an interaction between the subunits. We did observe 
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differences in the ability of LY379268 and L-AP4 to achieve maximal responses 
(LY379268 was a full agonist while L-AP4 only achieved a 70% maximal response), 
which could result from the presence of mGlu2 homodimers under these experimental 
conditions. In contrast, our data appear to be consistent with little to no expression of 
mGlu4 homodimers in our mGlu2/4 cell line. For example, the fact that PHCCC and 
4PAM-2 exhibit significantly decreased/no efficacy in potentiating L-AP4 responses 
suggests that most mGlu4 subunits in mGlu2/4 cell line appear to be in a complexed form. 
While we cannot definitively conclude that the receptors are forming strict heterodimers 
(as opposed to oligomers) in our system, the work of Doumazane et al. suggests that 
mGlu2 and mGlu4 appear to form heterodimers, rather than higher order oligomers, in 
vitro (Doumazane et al., 2011a). 
 
To overcome the caveat of mGlu2 homodimers in the stable cell line, we performed 
transient transfection experiments with a constant amount of mGlu4 or mGlu7 and 
variable amounts of mGlu2. Results from these studies suggest that expression of mGlu4 
specifically results in changes in the potency and cooperativity of an mGlu2 orthosteric 
agonist, and that alterations in mGlu4 PAM pharmacology are dependent on the amount 
of mGlu2 co-expression. Quite strikingly, 1/10 of the amount of mGlu2 compared to 
mGlu4 resulted in a nearly complete loss of potentiation of the glutamate response by 
PHCCC and 4PAM-2, suggesting that the heterointeractions may be dominant. 
 
We would note that, when mGlu2 and mGlu4 were co-transfected in similar amounts, the 
potency and Hill slope of the LY379268 response was the same as when mGlu2 is 
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expressed alone. The lack of effect of PHCCC and 4-PAM2, along with the similarities in 
Hill slope and potency once the amount of mGlu2 equals that of mGlu4, suggests that the 
interpretation that there are homomeric pools of mGlu2 and heteromeric mGlu2/4 under 
these conditions are most consistent with the current data. These data also recapitulate 
Kammermeier’s finding that mGlu2 homodimers existed when mGlu2 and mGlu4 were 
transfected with a 1:1 ratio but not a 1:3 ratio (Kammermeier, 2012). 
 
 
It has previously been shown that heterodimerization/hetero-interactions of receptors can 
substantially alter the effect of pharmacological reagents. For example, Gonzalez-Maeso 
et al. reported that 5-HT2A receptors interact with mGlu2 and form functional complexes 
in cerebral cortex (Gonzalez-Maeso et al., 2008). In the presence of this 5-HT2A/mGlu2 
complex, hallucinogenic 5-HT2A agonists triggered unique cellular responses, which may 
contribute to the pathogenesis of psychosis. The combination of unique orthosteric and 
allosteric ligands for mGlu2 and mGlu4 now allows us to pharmacologically interrogate 
the functional expression of mGlu4-containing heteromers at synapses in the CNS. For 
example, we found that VU0155041 potentiated L-AP4 responses at corticostriatal 
synapses, whereas PHCCC, which binds to a distinct allosteric site, showed no effect 
(Figure 3.1 and 3.13). In addition, the mGlu2 NAM MNI-137 was able to block L-AP4 
induced responses at the corticostriatal synapse, recapitulating the pharmacological 
profile of this compound in the mGlu2/4 cell line. 
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Although the results reported here cannot be seen as definitive evidence of mGlu2/4 
heterodimer formation in the CNS and could be explained by other potential mechanisms, 
such as involvement of other partner proteins, multiple lines of evidence are consistent 
with functional existence of predominantly mGlu2/4 heteromers at corticostriatal 
synapses: 1) time-resolved FRET studies by Doumazane et al. indicate that mGlu2 and 
mGlu4 form strict heterodimers when expressed in the same cells, 2) our co-
immunoprecipitation data using rodent striatal tissue demonstrate some type of physical 
interaction between mGlu2 and mGlu4 in this brain region, and 3) pharmacological 
properties at corticostriatal synapses recapitulate the results seen in the mGlu2/4 
recombinant cell line. Regardless of the mechanism, these studies provide compelling 
evidence that the function of mGlu receptors can be context-dependent and that mGlu4 
may display fundamentally distinct responses to selective allosteric modulators at 
different synapses upon coexpression of other mGlu receptor subtypes. 
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CHAPTER IV 
 
GENERAL DISCUSSION AND FUTURE DIRECTION 
 
Functional selectivity and therapeutic implications of mGlu allosteric modulators 
 
Seven transmembrane receptors (7TMRs) are intrinsic plasma membrane proteins that 
function as information transducers to pass stimuli from binding of natural ligands to 
activation of cytosolic signaling cascades. The fundamental mechanism of these actions 
is conformational changes of the receptors. Receptor proteins are dynamic molecules that 
are “breathing” and keep changing conformations, which are stabilized by natural ligands 
and synthetic orthosteric/allosteric reagents. Traditionally, these conformations are 
classified into “fully on”, “partially on” or “off” conformations using criteria of G protein 
activation.  
 
In addition to G proteins, however, numerous cytosolic proteins interact with various 
domains on the 7TMRs and constitute a part in the whole “breathing system”.  These 
proteins include arrestins and 7TMR interacting proteins, many of which are PDZ 
domain proteins. β-arrestin is able to recruit signaling molecules and induce long-lasting 
activation of ERK. Some examples of PDZ domain proteins include Na+/H+ exchange 
regulator factor 1 and PICK1. As each receptor conformation possesses a specific energy 
map, the affinities to signaling molecules also varies. It has recently been shown by 
bioluminescence resonance energy transfer that G protein and non-G protein pathways 
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are directly correlated with unique receptor conformations (Galandrin et al., 2008). 
Therefore, a ligand may not elicit responses in all signaling pathways and theoretically, 
no two ligands would produce the same receptor behavior in terms of signaling and 
receptor regulation. And such phenomenon is termed “functional selectivity” (Gesty-
Palmer and Luttrell, 2011).  
 
Even naturally occurring ligands may exhibit functionally selective effect. CCL19 and 
CCL20 represent the first examples, which induce different receptor desensitization 
profile on CCR7 receptor (Kohout et al., 2004). Other examples of orthosteric ligands 
stem from serotonin (5-HT) receptors. Orthosteric ligands at the 5-HT2A and 5-HT2C 
receptors have revealed different rank orders of agonists to stimulate phospholipase C 
versus phospholipase A2 pathways (Berg et al., 1998). In addition, there are now 
examples of ligands with inverse agonist properties in certain pathways but clear agonist 
activity in others (De Deurwaerdere et al., 2004). It has been observed as well, that 
compounds classified as “antagonists” can induce desensitization, internalization, and 
downregulation of receptors, a property that might be considered “agonistic” in nature 
(discussed in (Urban et al., 2007)).  
 
These observations deviate from “linear efficacy” and has breached the traditional view 
of signal propagation via the receptors. To better quantify such biased effects, useful 
measurements have been proposed to describe agonist effects. The term activity ratio, 
calculated using Max/EC50, serves to characterize the ability of a certain agonist to 
activate a given signaling pathway (Ehlert, 2005). When two pathways are compared, the 
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relative activity ratios can thus be used to determine preference of one pathway over the 
other as a measurement of signaling bias.  
 
As the search for more selective and “drug-like” 7TMR ligands has grown, the 
development of allosteric ligands has emerged. As these compounds bind to alternate 
sites on a 7TMR compared to the endogenous ligand, it might be expected that they could 
as well place the receptor in a unique structural conformation that might not be achieved, 
or at least favored, in their absence and result in preferential regulation of certain 
pathways in the presence of an allosteric ligand. For example, the mGlu5 PAM N-{4-
chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) methyl]phenyl}-2-
hydroxybenzamide (CPPHA), which binds to an alternate site on the mGlu5 receptor 
versus other PAMs (O'Brien et al., 2004), exhibits differential effects on calcium 
mobilization and ERK1/2 phosphorylation downstream of mGlu5 activation in cultured 
cortical astrocytes (Zhang et al., 2005). This is in contrast to the PAM 3,3′-
difluorobenzaldazine (DFB), which potentiates both responses similarly. Additionally, 
the study in Chapter II has introduced a second mechanism of functional selectivity 
where mGlu4 PAMs usually do not induce biased signaling yet can exhibit functional 
selective effects upon co-activation of a Gq coupled receptor. This indicates that the 
pharmacodynamics of compounds could be far more complicated in native environment 
and the substantial calcium response induced by mGlu4 PAMs could be of importance in 
the physiological and pathological conditions.  
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Functional selectivity could be used for rational design of drugs to maximize their 
therapeutic effects. In a case where functional selectivity may have therapeutic relevance, 
activation of the GPR109 receptor by nicotinic acid is effective is beneficial for 
dyslipidemia by lowering triglycerides and elevating high-density lipoprotein. However, 
serious side effects were observed in patients including cutaneous flushing (Pike, 2005). 
It has been shown that activation of the receptor by nicotinic acid activates the Gi 
signaling pathway, as well as phospholipase A2 activation followed by recruitment of β-
arrestins.  Studies using β-arrestin1 knockout mice revealed reduced dermal side effects 
while maintaining beneficial efficacies. In addition, MK-0354, a biased ligand that is 
devoid of β-arrestin recruitment, decreases serum levels of free fatty acids without 
inducing cutaneous flushing, and may represent an improved option for the treatment of 
dyslipidemia (Lai et al., 2008; Walters et al., 2009).  
 
β-arrestin signaling, however, can also be associated with additional therapeutic effects. 
For example, the β-adrenergic receptor blocker carvedilol acts as an inverse agonist in 
cAMP pathways but as an agonist in stimulating β-arrestin-mediated ERK 
phosphorylation (Wisler et al., 2007); this compound clinically shows advantages over 
other β-blockers in the treatment of heart failure. Another example comes from 
parathyroid hormone (PTH) receptor. Intermittent Activation of PTH receptor increases 
bone mass by stimulating osteoblasts. However, bone resorption can also occur through 
the coupling of osteoblasts to osteoclasts, which is not desired for the treatment of 
osteoporosis. Studies using β-arrestin2 knockout mice suggest that β-arrestin pathway 
limits PTH-induced osteoclastogenesis and contributes to increased bone mass (Ferrari et 
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al., 2005). Indeed, a biased agonist, D-Trp(12),Tyr(34))-PTH(7-34) (also named PTH-
betaarr), activates β-arrestin but not classic G protein signaling and induces bone 
formation without bone resorption, offering improved therapy for osteoporosis (Gesty-
Palmer et al., 2009). 
 
As to the biased signaling described in Chapter II, calcium is involved in various cellular 
functions including enzyme activation, signal-transduction, and electrophysiological 
responses. In the central nervous system, intracellular calcium mobilization is vital for 
neurotransmitter release and synaptic plasticity, including long-term potentiation and 
long-term depression. It is well studied that massive calcium mobilization mediated by 
7TMR cross-talk can have significant physiological implications. For example, mGlu1-
mediated calcium mobilization in Purkinje neurons is enhanced by concomitant 
activation of GABAB receptor (Kamikubo et al., 2007). Induction of such a calcium 
signal is suggested to act as a co-incidence detector for parallel- and climbing-fiber inputs, 
and is required for long-term depression at parallel-fiber–Purkinje cell synapses (Hirono 
et al., 2001; Wang et al., 2000). Similarly, potentiated calcium release by cross-talk 
between group I and group II mGluRs is shown to be critical for LTD in the perirhinal 
cortex under resting-membrane potentials (Cho et al., 2000). Therefore, signaling bias 
induced by mGlu4 PAMs could be utilized to treat disease conditions where calcium 
signaling of a Gq coupled receptor is desired in mGlu4-coexpressing cells but not in other 
tissues. On the other hand, however, an inappropriate intracellular calcium surge could 
induce apoptosis via activation of calpain (Camins et al., 2009). Therefore, caution may 
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need to be taken when mGlu4 PAMs are used in combination with other Gq receptor 
agonists.  
 
As more allosteric modulators are pursued in the hopes of achieving highly selective drug 
leads with good pharmacokinetic properties, further complexity induced by signal bias 
will continue to develop. While functional selectivity clearly complicates the use of 
compounds as general tools for probing receptor function and the progression of drugs 
with these properties through clinical development, there is great promise in this 
approach to eventually tailor drug therapy to a particular pathway or subset of signaling 
cascades to enhance therapeutic efficacy and/or reduce side effects. 
 
 
Receptor assembly-selective modulators of mGlu 
 
As mentioned above, allosterism of the receptor by ligands/modulators and interacting 
cytosolic proteins is essential for the signal transduction from environment into the cells. 
In addition to the guest allosterism and cytosolic allostery induced by these factors, 
receptor dimerization/oligomerization, as well as the lipid environment, comprise 
important components for the lateral allostery of 7TMRs (Kenakin and Miller, 2010).   
 
Although oligomerization of family A 7TMRs is a topic of extensive debate, family B 
7TMRs have recently been shown to form stable homodimers with the interacting 
interface at TM4 (Harikumar et al., 2008; Harikumar et al., 2007). In addition, family C 
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7TMRs (including mGlus) have shown compelling evidence for 
dimerization/oligomerization via both covalent and non-covalent bonds (Ray and 
Hauschild, 2000; Romano et al., 2001). 
  
As it is common to consider small molecules as receptor modulators, large receptor 
protomers may also induce conformational change to other protomers. It is thus important 
to realize two-way transmission by which receptor assembly can alter the behavior of 
small molecule modulators as well. This effect has been well established in cell line 
settings. Using the angiotensin receptor as an example, the agonist angiotensin II exhibits 
significantly increased efficacy when the receptor form a heterocomplex with bradykinin-
2 receptor (AbdAlla et al., 2000). Receptor dimerization may also affect intracellular 
signaling pathways. The G protein coupling of dopamine D2 receptor switches from Gi/o 
to Gq/11 when dimerized with dopamine D1 receptor (Rashid et al., 2007). In addition, 
SKF83959, a compound with no effect on either D1 or D2 monomer, activates the D1/D2 
heterodimer toward Gq/11 (Rashid et al., 2007). 
  
As dimerization/oligomerization of receptors clearly complicated the use of 
pharmaceutical reagents in in vivo settings. While selective compounds for receptor 
heterodimers help to avoid off-target effects, reagents that target all receptor assemblies 
may produce superior pharmaceutical efficacy. The results decribed in Chapter III also 
shed light on targeting distinct mGlu receptor assembly for drug development purposes. 
Taking PD as an example, highly selective mGlu4 PAMs have been developed from 
different chemical series and exhibit robust efficacy in preclinical rodent models. 
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Interestingly, both PHCCC and VU0155041 have been shown to reverse reserpine-
induced akinesia in rodents, suggesting that the anti-parkinsonian effects induced by 
mGlu4 PAMs may not be dependent on their activity at corticostriatal synapses and the 
assembly of mGlu2/4 heterodimer. However, corticostriatal synapses have been shown to 
be overactive in dopamine-depleted animals, which contributes to the loss of spines of 
striatal medium spiny neurons in PD (Garcia et al., 2010). The work of Picconi et al. 
demonstrates that dysregulated plasticity at these synapses, such as long-term depression 
and depotentiation, may underlie the mechanism of L-DOPA-induced dyskinesia (Picconi 
et al., 2011; Picconi et al., 2003). Therefore, mGlu4 PAMs that potentiate mGlu2/4 
heteromers may potentially provide additional therapeutic benefits, such as restoring 
morphology of striatal neurons and reversing L-DOPA-induced dyskinesias. In contrast, 
PAMs with selectivity for homodimers over heteromers might be beneficial for targeting 
mGlu4 activation in regions predominantly expressing mGlu4 alone if activation of 
heteromers proves to engender side effects. Additionally, selective mGlu2/4 modulators 
without mGlu2 or mGlu4 activity might also be of interest to achieve selective modulatory 
effect without affecting receptor homomers expressed in other regions.  
 
Although the signaling pathway of mGlu2/4 heterodimers does not deviate from the Gi/o 
coupling of each individual subtype, whether hetero-assembly lead to biased signal is of 
interest to explore. The effect of heterodimerization on other signaling cascades, 
especially arrestin binding, receptor desensitization, and internalization is worth further 
examination. Additionally, binding of modulators to one protomer on the heterodimers 
may also affect the pharmacology of allosteric sites on the other protomer. Detailed 
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studies using binding assays and functional assays are required to answer this question. 
Beside receptor dimerization, the effects of other interacting proteins and lipid bilayer 
composition on mGlu allosteric modulators are also largely unknown.  
 
In addition to mGlu2/4, other combinations of mGlu subtypes are co-localized in the CNS 
as well. For instance, mGlu4 and mGlu8 are co-expressed at the lateral olfactory tract-
piriform cortex synapse and suppress synaptic transmission (Jones et al., 2008). mGlu1 
and mGlu5 are co-expressed in several  neuronal populations including CA1 hippocampal 
pyramidal cells, striatal cholinergic interneurons, STN glutamatergic neurons and SNr 
GABAergic neurons (reviewed in (Valenti et al., 2002)). In addition, both mGlu7 and 
mGlu8 receptors modulate the Schaffer collateral-CA1 synapse in neonatal rats (Ayala et 
al., 2008). Although the assembly of other mGlu heteromers has yet to be determined in 
vivo, previous studies showing aberrant activity of mGlu-selective compounds may 
eventually be explained by heteromer-specific pharmacology (Ayala et al., 2008; 
Niswender et al., 2010). As characterization of other combinations of mGlu heteromers 
are underway, localizing mGlu homomers and heteromers will help elucidate the 
complexity of mGlu receptor signaling and function and eventually contribute to rational 
development of therapeutic reagents that target specific tissues through selective 
modulation of individual receptor assemblies. 
 
 
 
 
	   127	  	  
mGlu2/4 heteromer as a biomarker for Parkinson’s Disease 
 
As defined by the National Institutes of Health, a biomarker is a parameter that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention (Group, 
2001). Biomarkers for PD are of critical importance for patient treatment, since 
neuroprotective therapy starting at an advanced stage (after motor symptoms develop) is 
usually unsuccessful in progressive neurodegenerative diseases when compared to early 
stages.  
 
An ideal biomarker for PD should be able to facilitate PD treatment in the following 
aspects: 1) Aid in the early diagnosis of PD, preferably in a premotor period; 2) 
Accurately reflect disease progression; 3) Aid in therapeutic assignment of patients; and 4) 
Aid in accessing therapeutic efficacy of an intervention.  
 
Since its first description, the diagnosis of PD has been made based on motor deficits and 
associated non-motor symptoms. Recently, however, a number of biomarkers have been 
developed to aid in the diagnosis of PD, which can be further divided into pathological 
biomarkers, biochemical biomarkers, genetic biomarkers, electrophysiological 
biomarkers and imaging biomarkers. A recent study discovered that α-synuclein and 
Lewy bodies exist in the gut biopsies of PD patients that were obtained several years 
before the onset of motor symptoms (Shannon et al., 2012), serving as a potential 
pathological biomarker for early PD detection. Schmid et al. has shown that biochemical 
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profiling of the post-translational modification of α-synuclein in the cerebrospinal fluid or 
blood plasma might be a more relevant biomarker than total α-synuclein level (Schmid et 
al., 2013). Altered levels of brain-derived neurotrophic factor (BDNF) have been reported 
in the circulation (serum or plasma) of patients with PD. However, BDNF might not 
serve as a specific biomarker since decreased levels of this neurotrophic factor were also 
observed in other neurodegenerative disorders, including Alzheimer’s disease and 
Huntington’s disease, as well as mood disorders (major depression and bipolar disorder) 
(Teixeira et al., 2010). Mutations in five genes, such as α-synuclein, Parkin, PTEN-
induced kinase 1 (PINK1), DJ-1 and Leucine-rich repeat kinase 2 (LRRK2)] have been 
shown to lead to PD (Klein and Lohmann-Hedrich, 2007). However, these cases only 
account for 2–3% of all PD patients (Klein and Lohmann-Hedrich, 2007), and, even in 
these patients, age and environmental exposures greatly affect disease progression. 
Electrophysiologically, Hohlefeld et al. reported long-range temporal correlation of 
oscillation activities in subthalamic nucleus of PD patients, which can be modulated by 
levodopa treatment (Hohlefeld et al., 2012). However, the surgical procedures needed to 
measure neuronal activity in patients limited the usage of this parameter as a biomarker. 
In contrast, non-invasive imaging approaches have demonstrated great potential as a 
biomarker for PD diagnosis and treatment. For example, imaging of the dopamine 
transporter (DAT) with Single Photon Emission Computer Tomography (SPECT) is a 
main diagnostic imaging procedure for the assessment of patients with parkinsonism 
(Varrone and Halldin, 2012).  
 
	   129	  	  
Although with caveats, these existing biomarkers have brought valuable advances in PD 
diagnosis and the drug development process, including early proof-of-concept studies and 
dosing regimen determination. As PD is much more complicated than a single-cause 
disease, it is equally important to assign patients to suitable therapeutic interventions, and 
ideally, as quickly as possible to prevent further neurodegeneration. Unfortunately, no 
such biomarker has yet been developed. mGlu4 PAMs have been validated as potential 
therapeutic agents for PD with one possible mechanism being reduction of excessive 
GABA release at striatopallidal synapses (Marino et al., 2003; Valenti et al., 2003), 
thereby rebalancing basal ganglia circuitry. In addition, activation of mGlu4 inhibits 
glutamate release onto substantia nigra dopamine neurons (Valenti et al., 2005), which 
has been proposed to protect against excitotoxicity. However, our study described in 
Chapter III reveals that the efficacy of mGlu4 PAMs are differentially regulated by 
formation of mGlu2/4 heterodimers, with PHCCC losing efficacy and VU0155041 
retaining efficacy at the corticostriatal synapse. In addition, transient transfection 
experiment using cell lines suggests that the regulatory effect is dependent on the 
expression level of mGlu2. Due to the heterogeneity within PD population, it is 
conceivable that mGlu2 expression levels in the basal ganglia circuitry could vary among 
PD patients and may suggest that mGlu4 PAMs that are ideal for some patients may not 
benefit others with high mGlu2 expression colocalized with mGlu4. Therefore, with help 
from future development of selective and powerful imaging reagents for mGlu2 and 
mGlu4, the expression pattern of mGlu2 and mGlu4 within the basal represent an attractive 
biomarker in PD clinical trials and future clinical practice.   
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